---
library_name: setfit
tags:
- setfit
- sentence-transformers
- text-classification
- generated_from_setfit_trainer
metrics:
- accuracy
widget:
- text: "johnson johnsons cell therapy carvykti shows better survival rate in pretreated\
\ blood cancer patients finanzenat\n\n \
\ blob \n\natx atx dax dax dow dow estoxx\
\ estoxx nasdaq nasdaq öl öl euro euro chf chf gold gold \n\
\natx atx dax dax dow dow estoxx estoxx nasdaq nasdaq öl öl\
\ euro euro chf chf gold gold \n\n javascriptvoid\n\n \n\ndepot\
\ eröffnen\n\n javascriptvoid\n\n menujavascriptvoid\n\n börse\n\n aktien\n\
\ \n\n aktienkurse\n aktiensuche\n realtimekurse\n \n\n atxliste\n\
\ atx primeliste\n eurostoxxliste\n daxliste\n dow jonesliste\n nikkeiliste\n\
\ spliste\n rohstoffe\n devisen\n\n listen\n \n\n topflop\n indizes\n\
\ branchen\n\n termine\n \n\n hauptversammlung\n quartalszahlen\n \
\ wirtschaftsdaten\n dividendenausschüt\n\n dividenden\n börsesocial\n\n\
\ indizes\n \n\n listen\n \n\n topflop\n indizes\n\n realtimekurse\n\
\ \n\n indizes\n listen\n\n emerging markets\n\n zertifikate\n \n\
\n suche\n basiswerte\n \n\n indizes\n aktien\n baskets\n währungen\n\
\ rohstoffe\n zinsen anleihen\n sonstige\n\n produkttypen\n \n\n \
\ airbag\n aktienanleihen\n alpha\n basket\n bonus\n discount\n exotische\
\ os\n express\n faktor tracker\n indextracker\n inlineos\n garantie\n\
\ knockout\n optionsscheine\n outperformance\n sonst zertifikate\n sprint\n\
\n tools\n \n\n zertifikatematrix\n emittentenmatrix\n knockout map\n\
\n news\n neuemissionen\n\n hebelprodukte\n \n\n ossuche\n kosuche\n\
\ basiswerte\n \n\n indizes\n aktien\n baskets\n währungen\n rohstoffe\n\
\ zinsen anleihen\n sonstige\n\n produkttypen\n \n\n airbag\n aktienanleihen\n\
\ alpha\n basket\n bonus\n discount\n exotische os\n express\n faktor\
\ tracker\n indextracker\n inlineos\n garantie\n knockout\n optionsscheine\n\
\ outperformance\n sonst zertifikate\n sprint\n\n tools\n \n\n zertifikatematrix\n\
\ emittentenmatrix\n knockout map\n\n news\n neuemissionen\n\n fonds\n\
\ \n\n suche\n news\n kvgs\n\n etf\n \n\n suche\n news\n kvgs\n\
\n anleihen\n \n\n suche\n news\n\n rohstoffe\n \n\n news\n \
\ realtimekurse\n goldmünzen\n\n devisen\n \n\n news\n währungsrechner\n\
\ realtimekurse\n kryptowährungen\n kryptobroker vergleich\n\n zinsen\n\
\ \n\n news\n libor\n euribor\n leitzins\n\n cfds\n \n\n news\n\
\n trading\n \n\n hebelprodukte\n optionsscheine\n realtimekurse\n\
\ \n\n atxliste\n atx primeliste\n eurostoxxliste\n daxliste\n rohstoffe\n\
\ devisen\n\n bitcoin kaufen\n\n kryptos\n brokervergleiche\n \n\n\
\ brokervergleich\n kryptobrokervergleich\n cfdbrokervergleich\n\n forum\n\
\n news analysen\n\n news\n \n\n ressorts\n \n\n aktien\n anleihen\n\
\ cfds\n devisen\n etf\n fonds\n rohstoffe\n zertifikate\n private\
\ finanzen\n zinsen\n\n rubriken\n \n\n chartanalysen\n emittentennews\n\
\ fondsgesellschaft news\n heute im fokus\n interviews\n konjunktur\n\
\ zinsen\n\n quellen\n \n\n apa\n aktiencheck\n businesswire\n \
\ dow jones newswires\n dpaafx\n\n heute im fokus\n nachrichtenarchiv\n\n\
\ analysen\n experten kolumnen\n atx news\n\n myfinanzen\n\n anmelden\n\
\ registrieren\n passwort vergessen\n mein profil\n portfolio\n watchlist\n\
\n zero depot\n etfsparplan\n krypto kaufen\n ratgeber\n\n suchenjavascriptvoid\n\
\ \n \n\nanmelden registrieren fan werden\n\n \n\n börse börse\n news\
\ analysen news analysen\n myfinanzen myfinanzen\n zero depot zero depot\n\
\ etfsparplan etfsparplan\n krypto kaufen krypto kaufen\n ratgeber ratgeber\n\
\n news news\n analysen analysen\n experten kolumnen experten kolumnen\n\
\ atx news atx news\n\n ressorts ressorts\n \n aktien aktien\n \
\ anleihen anleihen\n cfds cfds\n devisen devisen\n etf\
\ etf\n fonds fonds\n rohstoffe rohstoffe\n zertifikate zertifikate\n\
\ private finanzen private finanzen\n zinsen zinsen\n rubriken rubriken\n\
\ \n chartanalysen chartanalysen\n emittentennews emittentennews\n\
\ fondsgesellschaft news fondsgesellschaft news\n heute im fokus heute\
\ im fokus\n interviews interviews\n konjunktur konjunktur\n \
\ zinsen zinsen\n quellen quellen\n \n apa apa\n aktiencheck\
\ aktiencheck\n businesswire businesswire\n dow jones newswires dow\
\ jones newswires\n dpaafx dpaafx\n heute im fokus heute im fokus\n \
\ nachrichtenarchiv nachrichtenarchiv\n\nhome home »\n\naktien aktien »\n\nin\
\ holdingsaktie in holdingsaktie »\n\nnachrichten zu in holdings nachrichten zu\
\ in holdings »\n\njohnson johnsons cell therapy carvykti shows better survival\
\ rate in pretreated blood cancer patients\n\nin holdings aktie isin jp in holdings\
\ co ltd registered shs aktie\n\n\nin holdings aktie isin jp in holdings co ltd\
\ registered shs aktie\n\n\njavascriptvoid druckansicht\n\nkurse charts realtime\n\
\nnews analysen\n\nfundamental\n\nunternehmen\n\nzugeh wertpapiere\n\naktion\n\
\nkurs chart in holdings co ltd registered shs kurs\n\nchart groß in holdings\
\ co ltd registered shs chartanalyse\n\nnews adhoc in holdings co ltd registered\
\ shs news adhoc\n\nbilanzguv in holdings co ltd registered shs bilanzguv\n\n\
termine in holdings co ltd registered shs termine\n\nzertifikate in holdings co\
\ ltd registered shs zertifikate\n\nportfoliojavascriptvoid\n\ntimes sales in\
\ holdings co ltd registered shs times and sales\n\nchartvergleichjavascriptoeffneneuesfenster\
\ in holdings co ltd registered shs chartvergleich\n\nanalysen in holdings co\
\ ltd registered shs analysen\n\nschätzungen in holdings co ltd registered shs\
\ schätzungen\n\nprofil in holdings co ltd registered shs profil\n\noptionsscheine\
\ in holdings co ltd registered shs optionsscheine\n\nwatchlistjavascriptvoid\n\
\nbörsenplätze in holdings co ltd registered shs börsenplätze\n\nrealtime push\
\ in holdings co ltd registered shs realtime push\n\nkursziele in holdings co\
\ ltd registered shs kursziele\n\ndividendegv in holdings co ltd registered shs\
\ dividendegv\n\nknockouts in holdings co ltd registered shs knockouts\n\nhistorisch\
\ historisch in holdings\n\nanalysen in holdings co ltd registered shs fundamentalanalyse\n\
\n\n\nkurse charts realtime\n\nkurs chart in holdings co ltd registered shs\
\ kurs\n\ntimes sales in holdings co ltd registered shs times and sales\n\nbörsenplätze\
\ in holdings co ltd registered shs börsenplätze\n\nhistorisch historisch in holdings\n\
\n\n\n\n\nnews analysen\n\nnews adhoc in holdings co ltd registered shs news\
\ adhoc\n\nanalysen in holdings co ltd registered shs analysen\n\nkursziele in\
\ holdings co ltd registered shs kursziele\n\n\n\n\n\nfundamental\n\nbilanzguv\
\ in holdings co ltd registered shs bilanzguv\n\nschätzungen in holdings co ltd\
\ registered shs schätzungen\n\ndividendegv in holdings co ltd registered shs\
\ dividendegv\n\nanalysen in holdings co ltd registered shs fundamentalanalyse\n\
\n\n\n\n\nunternehmen\n\ntermine in holdings co ltd registered shs termine\n\n\
profil in holdings co ltd registered shs profil\n\n\n\n\n\nzugeh wertpapiere\n\
\nzertifikate in holdings co ltd registered shs zertifikate\n\noptionsscheine\
\ in holdings co ltd registered shs optionsscheine\n\nknockouts in holdings co\
\ ltd registered shs knockouts\n\n\n\n \n\njohnson johnsons cell therapy carvykti\
\ shows better survival rate in pretreated blood cancer patients\n\n\na\n\na\n\
\nteilen\n\ndrucken\n\nthis article johnson johnsons cell therapy carvykti shows\
\ better survival rate in pretreated blood cancer patients originally appeared\
\ on benzingacomweiter zum vollständigen artikel bei benzinga zum vollständigen\
\ artikel weiter zum vollständigen artikel bei benzinga\n\n\n\nder finanzenat\
\ ratgeber für aktien \nwenn sie mehr über das thema aktien erfahren wollen finden\
\ sie in unserem ratgeber viele interessante artikel dazu \njetzt informieren\n\
\n \n\n \n\ndas könnte sie auch interessieren\n\nempfohlen von \n\nnachrichten\
\ zu in holdings co ltd registered shsmehr nachrichten nachrichten zu in holdings\
\ co ltd registered shs\n\n\n relevant\n alle\n vom unternehmen\n \n\n\
\ \n\n\n\nsuperreichensteuer so viel könnte sie in deutschland einbringen superreichensteuer\
\ so viel könnte sie in deutschland einbringen spiegel online spiegel online\n\
\n\n\ninflation energie und nahrungsmittel dämpfen inflation in deutschland inflation\
\ energie und nahrungsmittel dämpfen inflation in deutschland handelsblatt handelsblatt\n\
\n\n\nchemie basf schließt zwei weitere anlagen in deutschland chemie basf schließt\
\ zwei weitere anlagen in deutschland handelsblatt handelsblatt\n\n\n\nautobauer\
\ bmw ruft in den usa fast autos zurück autobauer bmw ruft in den usa fast\
\ autos zurück handelsblatt handelsblatt\n\n\n\nuk economy grows by in may uk\
\ economy grows by in may financial times financial times\n\n\n\nciti fined mn\
\ for compliance failures in further blow to overhaul citi fined mn for compliance\
\ failures in further blow to overhaul financial times financial times\n\n\n\n\
citi fined mn for compliance failures in further blow to overhaul citi fined mn\
\ for compliance failures in further blow to overhaul financial times financial\
\ times\n\n\n\nuk announces biggest overhaul of listings regime in decades uk\
\ announces biggest overhaul of listings regime in decades financial times financial\
\ times\n\nanalysen zu in holdings co ltd registered shsmehr analysen analysen\
\ zu in holdings co ltd registered shs\n\n\n alle\n buy\n hold\n sell\n\
\ \n\n \n\n \n\n \n\n \n\n \n\n \n\neintrag hinzufügen eintrag bearbeiten\n\
\nhinweis sie möchten dieses wertpapier günstig handeln sparen sie sich unnötige\
\ gebühren bei finanzennet brokerage handeln sie ihre wertpapiere für nur euro\
\ orderprovision pro trade hier informieren\n\nerfolgreich hinzugefügt zu portfoliowatchlist\
\ wechseln\n\nes ist ein fehler aufgetreten\n\nkein portfolio vorhanden bitte\
\ zusätzlich den namen des neuen portfolios angeben keine watchlisten vorhanden\
\ bitte zusätzlich den namen der neuen watchlist angeben\n\n \n\nportfolioname\
\ watchlistname\n\n \n\nportfolio\n\nname\n\ntyp\n\nisin\n\nbörse\n\nanzahl\n\n\
aktueller kurs\n\nkurszeit\n\nkaufpreis\n\n \n\nkaufdatum\n\n \n\nkaufwert\n\n\
\ eur\n\nhinzufügen speichern\n\nnewssuche\n\n\ngojavascriptvoid\n\naktien in\
\ diesem artikel\n\n\n \n\nin holdings co ltd registered shs\n\n\n\n\n\nin holdings\
\ co ltd registered shsblob\n\nbörse aktuell live ticker\n\n\natx schließt in\
\ rot dax schließlich tiefer asiens börsen letztlich im minus der heimische\
\ aktienmarkt zeigte sich in rot der deutsche aktienmarkt präsentierte sich am\
\ mittwoch leichter die usbörsen weisen kursverluste aus die börsen in fernost\
\ verbuchten zur wochenmitte verluste\n\nnachrichten\n\n\n nachrichten zu aktien\n\
\ alle nachrichten\n\n\n\nkering stimmt auf weiteren gewinneinbruch ein gucci\
\ erneut schwach kering stimmt auf weiteren gewinneinbruch ein gucci erneut schwach\n\
\n\n\ncairn homes plc holdings in company cairn homes plc holdings in company\n\
\n\n\nausblick lpkf laser electronics zieht bilanz zum abgelaufenen quartal ausblick\
\ lpkf laser electronics zieht bilanz zum abgelaufenen quartal\n\n\n\nfuller smith\
\ turner plc transaction in own shares fuller smith turner plc transaction in\
\ own shares\n\n\n\nteslas q disappoints but theres more to the story teslas q\
\ disappoints but theres more to the story\n\n\n\ngericht pauschaler geldbetrag\
\ für bezahlkarte rechtswidrig gericht pauschaler geldbetrag für bezahlkarte rechtswidrig\n\
\n\n\nreise israelischer delegation nach katar verschiebt sich reise israelischer\
\ delegation nach katar verschiebt sich\n\n\n\nausblick totalenergies stellt quartalsergebnis\
\ zum abgelaufenen jahresviertel vor ausblick totalenergies stellt quartalsergebnis\
\ zum abgelaufenen jahresviertel vor\n\n\n\neaton declares quarterly dividend\
\ payable august eaton declares quarterly dividend payable august \n\n\n\n\
aktie im fokus alphabet leiden unter sorgen um das kigeschäft aktie im fokus alphabet\
\ leiden unter sorgen um das kigeschäft\n\npagehit\n\naktien kaufen zu \ntopkonditionen\n\
\naktien etfs derivate kryptos und mehr – jetzt für euro pro trade handeln zzgl\
\ marktüblicher spreads\n\njetzt informieren\n\nfinanzennet apps\n\n finanzennet\
\ ios appblob android appblob\n\nfinanzennet appsblob\n\n \n\noskarblob etfsparplan\n\
\noskar ist der einfache und intelligente etfsparplan er übernimmt die etfauswahl\
\ ist steuersmart transparent und kostengünstig\n\njetzt mehr erfahren\n\n finanzenat\
\ bei facebook finanzenat rss feed\n\nwie bewerten sie diese seite\n\nschlecht\
\ sehr gut\n\n \n \naktien atx dax eurostoxx dow jones nasdaq nikkei\
\ sp \n \nkontakt impressum werbung\n\nsitemap datenschutz disclaimer \
\ agb privatsphäreeinstellungen\n\n \n\nfür die aufgeführten inhalte kann\
\ keine gewährleistung für die vollständigkeit richtigkeit und genauigkeit übernommen\
\ werden \nkursinformationen von six financial information deutschland gmbh verzögerung\
\ min nasdaq nyse min \n© finanzennet gmbh\n\nwerbehinweise die billigung\
\ des basisprospekts durch die bundesanstalt für finanzdienstleistungsaufsicht\
\ ist nicht als ihre befürwortung der angebotenen wertpapiere zu verstehen wir\
\ empfehlen interessenten und potenziellen anlegern den basisprospekt und die\
\ endgültigen bedingungen zu lesen bevor sie eine anlageentscheidung treffen um\
\ sich möglichst umfassend zu informieren insbesondere über die potenziellen risiken\
\ und chancen des wertpapiers sie sind im begriff ein produkt zu erwerben das\
\ nicht einfach ist und schwer zu verstehen sein kann\n\nhinweis zu plus der\
\ kleinanlegerkonten verlieren geld beim cfdhandel mit diesem anbieter sie sollten\
\ überlegen ob sie es sich leisten können das hohe risiko einzugehen ihr geld\
\ zu verlieren plusuk ltd ist zugelassen und reguliert durch financial conduct\
\ authority frn pluscy ltd authorized regulated by cysec \n\n \nwährungsrechner \
\ news devisen dollarkurs aktienkurse bitcoin rohstoffe fonds"
- text: "expanding roles new approaches for pharmacists in managing graftvshost disease\n\
\n \n\n contemporary clinic contemporary clinic\n otc guide otc guide\n\
\ pharmacy times\n \n ptce ptce\n pharmacist moms group pharmacist\
\ moms group\n\n blob logo\n\nnews\n\nall news releases\n\nmedia\n\nall videos\
\ detail corner world news exchange consult pearls webcast voices\n\nconferences\n\
\nconference coverage listing\n\npublications\n\npharmacy times practice in focus\
\ oncology practice in focus health systems careers publications the publications\
\ submission a manuscript a peer reviewer\n\nclinical\n\nb compounding pharmacy\
\ disease dermatitis disorder health cancer difficile health cancer kidney disease\
\ lymphocytic leukemia cancer and cold health eye disease care updates of pharmacy\
\ cancer health failure disease cancer degeneration health myeloma sclerosis cancer\
\ management disease heroes management cancer arthritis health syncytial virus\
\ arthritis cancer pharmacy and supplements management health\n\nevents\n\nupcoming\
\ events webinars\n\ncmece\n\nresources\n\nclinical forum patient for the pharmacist\
\ tools\n\nsubscribe\n\n blob logo\n\nspotlight\n\ncommunityretail technician\n\
\nclinical role\n\ncommunityretail technician pharmacy\n\nclinical\n\ncoronavirus\
\ health health failure and supplements\n\nsupplement spotlight\n\noctober pharmacy\
\ technician edition\n\nnews\n\nall news releases\n\nmedia\n\nall videos detail\
\ corner world news exchange consult pearls webcast voices\n\nconferences\n\n\
conference coverage listing\n\npublications\n\npharmacy times practice in focus\
\ oncology practice in focus health systems careers publications the publications\
\ submission a manuscript a peer reviewer\n\nclinical\n\nb compounding pharmacy\
\ disease dermatitis disorder health cancer difficile health cancer kidney disease\
\ lymphocytic leukemia cancer and cold health eye disease care updates of pharmacy\
\ cancer health failure disease cancer degeneration health myeloma sclerosis cancer\
\ management disease heroes management cancer arthritis health syncytial virus\
\ arthritis cancer pharmacy and supplements management health\n\nevents\n\nupcoming\
\ events webinars\n\ncmece\n\nresources\n\nclinical forum patient for the pharmacist\
\ tools\n\nsubscribe\n\nadvertisement\n\nclinical role \n\ncommunityretail\n\n\
\ hospital\n\n oncology\n\n pharmacy technician\n\n student\n\nexpanding roles\
\ new approaches for pharmacists in managing graftvshost disease\n\n\njune \n\
\nby gillian mcgovern assistant editor\n\npublication\n\narticle\n\npharmacy practice\
\ in focus oncologyjune \n\nvolume \n\nissue \n\n\n\nwhen treating patients with\
\ graftvshost disease pharmacists are often responsible for selecting treatment\
\ regimens while navigating other spheres of care\n\n blob medical panelists\
\ credit africa studio stockadobecom\n\n credit africa studio stockadobecom\n\
\n \n\nthere is no consensus when treating patients with graftvshost disease gvhd\
\ because of the varying disease states and different interpretations among providers\
\ explained amir ali pharmd bcop during a pharmacy times clinical forum discussion\
\ ali is a clinical pharmacist specialist in hematologyoncology and bone marrow\
\ transplant bmt at the university of southern california norris comprehensive\
\ cancer center in los angeles as the treatment landscape for gvhd continues to\
\ develop and new data emerge pharmacists can develop more individualized regimens\
\ for patients while finding their roles in treatment management are expanding\n\
\nalthough steroids are typically the universal option for frontline treatment\
\ ali emphasized that longterm steroid use isn’t ideal due to adverse events aes—such\
\ as fibrosis which can be irreversible in patients with chronic gvhd cgvhd—and\
\ the possibility of disease becoming refractory according to ali there are only\
\ fdaapproved agents for the treatment of patients with gvhd ibrutinib imbruvica\
\ janssen biotech inc pharmacyclics llc which was approved in belumosudil rezurock\
\ kadmon pharmaceuticals llc which was approved in july and ruxolitinib jakafi\
\ incyte which was approved in september and has indications for cgvhd\n\nas\
\ an example ali highlighted a patient who had cgvhd in the skin and joints further\
\ he decided not to treat the patient with ibrutinib due to the lack of efficacy\
\ shown in data from clinical trials using other data he chose to treat the patient\
\ with belumosudil because it demonstrated response rates in approximately of\
\ patients who received the treatment realworld data ali said can be important\
\ for health care providers when determining individualized treatment plans for\
\ patients\n\nbecause steroids aren’t ideal in the long term there are different\
\ practices in place to remove patients from this highdose treatment as soon as\
\ possible whether it’s adhering to a particular timeline or tapering according\
\ to tina gu pharmd bcop clinical pharmacist in pediatric hematologyoncology and\
\ bmt at the university of california san francisco ucsf benioff children’s hospital\
\ her practice tends to taper patients off steroids before they develop refractory\
\ disease or experience aes\n\n“our standard is to try to start tapering after\
\ weeks of highdose steroids but what we’re seeing more at our hospital is adding\
\ a second agent earlier on so we’re not even waiting for patients with gvhd to\
\ develop steroidrefractory disease and we’re adding a second oral agent earlier\
\ because our providers are anticipating that it’s already going to be hard to\
\ taper patients off their steroids so by adding the steroidsparing agent providers\
\ may be more successful in getting them off these agents” gu said during the\
\ discussion\n\nfurthermore during the tapering of steroids patients may experience\
\ cgvhdrelated exacerbation or recurrence pharmacists may want to increase the\
\ dose or begin switching the patient to a new drug sandy on pharmd clinical pharmacist\
\ in hematology and bmt at stanford health care in california noted that although\
\ her institution wants patients off steroids as soon as possible she continues\
\ the use of steroids because she is already considering what additional treatment\
\ can be used currently and in secondline treatment additionally for patients\
\ who experience a partial response to steroids the next steps can be determined\
\ depending on which organ system is involved in the patient’s gvhd state\n\n\
angela lee pharmd bcop clinical pharmacist in hematologyoncology bmt and cellular\
\ therapies at ucsf said that addon treatments can rely heavily on patient characteristics\
\ such as their response to steroids which organs are affected by their gvhd or\
\ the individual drug’s mechanism of action\n\n“addon treatment also depends on\
\ the organ affected because there are some data that show belumosudil may be\
\ more effective in the lung setting for patients who present with lung disease\
\ up front that may be something that is considered along with their regimen”\
\ lee said during the discussion “for what ali was mentioning earlier it also\
\ depends on the mechanism of action such as ruxolitinib if providers want to\
\ target cgvhd earlier they might want to consider using that first”\n\npharmacists\
\ particularly bmt pharmacists have a significant role when caring for patients\
\ with gvhd according to the panelists pharmacists are typically the most constant\
\ health care professionals whom patients see when receiving treatment for their\
\ disease state especially in gvhd treatment pharmacists tend to know the data\
\ better than other health care professionals and help make recommendations and\
\ decisions for tapering medications or treatment selection according to the panelists\n\
\nadditionally pharmacists are also the ones who are planning treatment pathways\
\ around insurance issues lee explained that she and other pharmacists at her\
\ practice must often plan far in advance because certain insurance companies\
\ are not always specific in what they are able to cover or may not know which\
\ limited distribution specialty pharmacies carry certain medications such as\
\ ruxolitinib ali echoed this point by emphasizing his experiences when treating\
\ patients\n\n“even coming up with treatments we do that all the time i have providers\
\ come up to me almost daily and share a case with me and say ‘this is the situation’\
\ and every practice is different but that’s the direction we’re heading in” ali\
\ explained during the discussion “so having a pharmacist on the patient’s health\
\ care team to break everything down is extremely important”\n\ndownload issue\
\ pdf\n\ndownload ris\n\narticles in this issue\n\n \n\n \n\n medical panelists\
\ credit africa studio stockadobecomblob expanding roles new approaches for\
\ pharmacists in managing graftvshost disease red blood cells credit ktsdesign\
\ stockadobecomblob addressing challenges when implementing bispecific antibodies\
\ in diverse settings lgbtqia couple holding hands credit nong stockadobecomblob\
\ enhancing cancer care sogi data collection for sexual and gender minority patients\
\ remains critical blood sample positive for multiple myeloma credit luchschenf\
\ stockadobecomblob operationalizing bispecific antibodies across academic and\
\ community oncology centers in hematologic malignancies woman with cancer \
\ credit africa studio stockadobecomblob end of ocm brings dropoff in valuebased\
\ care volume new questions pharmacist helping a patient credit yuri arcurspeopleimagescom\
\ stockadobecomblob breaking down silos in oncology care enhancing communication\
\ and education for improved patient outcomes health care provider and patient\
\ credit c davidspeopleimagescom stockadobecomblob the chemotherapist subcutaneous\
\ injection credit photobytawat stockadobecomblob pharmacy departmentdriven\
\ initiative to reduce subcutaneous daratumumab observation time older woman\
\ receiving chemotherapy credit seventyfour stockadobecomblob drug shortages\
\ in community oncology ensuring access to chemotherapy cll in blood credit\
\ drmicrobe stockadobecomblob covalent btk inhibitors a review of the evidence\
\ in chronic lymphocytic leukemia chemotherapy iv drip credit zlikovec stockadobecomblob\
\ addressing the ethical complications of drug shortages woman with cancer and\
\ her daughter credit africa studio stockadobecomblob sex and gender inequalities\
\ in oncology care and research persist patient receiving chemotherapy through\
\ iv credit denis stockadobecom blob navigating oncology drug shortages ethical\
\ frameworks and strategic management\n\nrecent videos\n\n credit © anastasiia\
\ stockadobecomblob clinical perspectives on gprcdtargeted car tcell therapy\
\ for multiple myeloma lgbtqia pride credit lazyllama stockadobecom blob expert\
\ having conversations and practicing cultural competency with lgbtqia patients\
\ credit © анастасія стягайло stockadobecomblob breakthroughs in cutaneous\
\ malignancy treatments exploring innovations in asco data breast cancer treatment\
\ credit © siam stockadobecomblob innovations in breast cancer therapy key updates\
\ and clinical implications credit © dragana gordic stockadobecomblob enhancing\
\ qualityoflife care the vital role of pharmacists in supportive care during cancer\
\ treatment small cell lung cancer treatment credit © craftyimago stockadobecomblob\
\ exploring innovative targeted therapies for relapsed sclc navigating the complex\
\ landscape of cell and gene therapy challenges and solutionsblob navigating the\
\ complex landscape of cell and gene therapy challenges and solutions lymphoma\
\ opc asco hodgkin lymphomablob insights into the evolving landscape of hematology\
\ treatment car t cell therapy multiple myeloma credit © lusimila stockadobecomblob\
\ from research to practice new treatment modalities for patients with multiple\
\ myeloma paloma trial advances sc amivantamab lazertinib for advanced nsclc\
\ with egfr mutations to the first lineblob paloma trial advances sc amivantamab\
\ lazertinib for advanced nsclc with egfr mutations to the first line\n\nrelated\
\ content\n\nadvertisement\n\n man getting vaccinated by a woman both wearing\
\ masksblob\n\npatients with cancer have unique considerations for influenza vaccination\n\
\nsamantha gorski pharmd candidate\n\njuly rd article\n\n pharmacy focus oncology\
\ edition benefits of subcutaneous amivantamab for lung cancer treatmentblob\n\
\npharmacy focus oncology edition benefits of subcutaneous amivantamab for lung\
\ cancer treatment\n\njune th podcast\n\n orange slice symbolizing vitamin c\
\ is eating the cut out piece on orange background credit cagkan stockadobecom\
\ blob\n\norange juice can aid absorption of iron\n\nkennedy ferruggia assistant\
\ editor\n\njuly rd article\n\n pharmacy focus oncology edition pharmacists\
\ pivotal role in driving clinical trial researchblob\n\npharmacy focus oncology\
\ edition pharmacists pivotal role in driving clinical trial research\n\nmay th\
\ podcast\n\n pharmacy students social determinants of health credit luckybusiness\
\ stockadobecomblob\n\nexperts social determinants of health should be as important\
\ as clinical content in pharmacy curricula\n\nashley gallagher associate editor\n\
\njuly nd article\n\n a doctor hands over a strip of pills to an elderly patient\
\ ensuring proper medication management credit sommersby stockadobecom blob\n\
\nstay aware of common highalert medications\n\nkathleen kenny pharmd rph\n\n\
july nd article\n\nrelated content\n\noncology\n\n\n\npublications\n\n\n\nclinical\
\ forum\n\nadvertisement\n\n man getting vaccinated by a woman both wearing masksblob\n\
\npatients with cancer have unique considerations for influenza vaccination\n\n\
samantha gorski pharmd candidate\n\njuly rd article\n\n pharmacy focus oncology\
\ edition benefits of subcutaneous amivantamab for lung cancer treatmentblob\n\
\npharmacy focus oncology edition benefits of subcutaneous amivantamab for lung\
\ cancer treatment\n\njune th podcast\n\n orange slice symbolizing vitamin c\
\ is eating the cut out piece on orange background credit cagkan stockadobecom\
\ blob\n\norange juice can aid absorption of iron\n\nkennedy ferruggia assistant\
\ editor\n\njuly rd article\n\n pharmacy focus oncology edition pharmacists\
\ pivotal role in driving clinical trial researchblob\n\npharmacy focus oncology\
\ edition pharmacists pivotal role in driving clinical trial research\n\nmay th\
\ podcast\n\n pharmacy students social determinants of health credit luckybusiness\
\ stockadobecomblob\n\nexperts social determinants of health should be as important\
\ as clinical content in pharmacy curricula\n\nashley gallagher associate editor\n\
\njuly nd article\n\n a doctor hands over a strip of pills to an elderly patient\
\ ensuring proper medication management credit sommersby stockadobecom blob\n\
\nstay aware of common highalert medications\n\nkathleen kenny pharmd rph\n\n\
july nd article\n\nadvertisement\n\nrecent content\n\n blob teenage girl looking\
\ at herself in the mirror credit halfpoint stockadobecom analysis determines\
\ body dysmorphic disorder is the most common in adolescent girls blob rsv vaccine\
\ vial behind a lung ct scan pharmacists play key role in selecting best rsv vaccine\
\ for older adults blob man getting vaccinated by a woman both wearing masks\
\ patients with cancer have unique considerations for influenza vaccination blob\
\ diabetes meal replacement credit jagcz stockadobecom intermittent fasting\
\ and meal replacements improved shortterm glycemia\n\nview more recent content\n\
\nadvertisement\n\nconsent preferences\n\nabout us\n\nclinical forums\n\nadvertise\n\
\ncontact us\n\neditorial staff\n\nprivacy policy\n\nterms conditions\n\ndo not\
\ sell my information\n\ncontact info\n\n commerce drive \ncranbury nj \n\ntel\n\
\n blob blob\n\n\n\n© mjh life sciences \n \nall rights reserved"
- text: "takeda commits m for chance to bring immunotherapy to alzheimer’s disease\
\ medcity news\n\n \n\n twitter\n\
\ facebook\n linkedin\n rss\n subscribe via email\n\n newsletter signup\n\
\ send tipsmailto\n\nopen navigation\n\nmedcity news\n\ntoggle search\n\n \
\ news\n health tech\n biopharma\n devices diagnostics\n \
\ consumer employer\n contributors\n medcity influencers\n \
\ medcitizens\n events\n invest\n invest digital health\n \
\ engage at hlth\n podcasts\n research\n newsletters\n\n newsletter signup\n\
\ send tipsmailto\n\n twitter\n facebook\n linkedin\n rss\n subscribe\
\ via email\n\n search for search\n\nbiopharma pharma\n\ntakeda commits m for\
\ chance to bring immunotherapy to alzheimer’s disease\n\n\ntakeda pharmaceutical\
\ has secured an option on an alzheimer’s disease immunotherapy from ac immune\
\ that is on track to report its first phase data later this quarter exercising\
\ the option would make takeda responsible for phase testing of the therapy putting\
\ ac immune in line for up to billion in milestone payments\n\nby frank vinluan\
\ on may \n\nshare\n\nshare options\n\nshare a link too this article\n\n copy\
\ link copy link\n emailmailtobody\n facebook\n linkedin\n x\n\n \n\n\
alzheimer’s disease can be treated with antibody drugs that reduce levels of amyloid\
\ beta protein in the brain clinicalstage biotech company ac immune is developing\
\ a novel therapy that sparks the immune system to clear away amyloid plaque and\
\ takeda pharmaceutical sees enough promise in this approach to commit million\
\ for the opportunity to pick up this experimental therapy\n\nthe ac immune drug\
\ codenamed aci is currently being evaluated in the phase portion of a phase\
\ b study under the deal terms announced monday takeda’s upfront payment gives\
\ it an exclusive option to license global rights to this immunotherapy\n\naci\
\ is an immunogenic peptide that is presented to the immune system’s b cells in\
\ a way that mimics the pathological form of amyloid beta this presentation is\
\ intended to spark activity from antibodies that bind to pathological forms of\
\ the protein in preclinical research lausanne switzerlandbased ac immune has\
\ reported that the drug led to higher blood levels of immunoglobulin g antibodies\
\ that were associated with reduction in amyloid plaque in tests in monkeys ac\
\ immune reported a favorable safety profile for the drug\n\nsponsored content\n\
\n \n\n integrated enrollment platforms and consumer assistance centers the strongest\
\ advantage for statebased exchanges\n\nin the everevolving landscape of statebased\
\ health insurance exchanges the convergence of technology and customer service\
\ is reshaping how these exchanges operate the increasing advent of automation\
\ and artificial intelligence ai is rapidly dismantling the traditional business\
\ model that relies on the siloing of technology and customer service centers\n\
\nby shankar srinivasan cofounder and general manager getinsured and jason sparks\
\ vp of project management and implementation getinsured\n\nac immune is responsible\
\ for completing the placebocontrolled phase b study which is evaluating for aci\
\ in patients with early alzheimer’s the study is also testing the immunotherapy\
\ as a treatment for patients with down syndrome under the takeda agreement the\
\ japanese pharmaceutical giant may exercise its option after it receives predefined\
\ clinical data on the first three alzheimer’s patient cohorts from the ongoing\
\ study ac immune said in a regulatory filing the first phase data on amyloid\
\ plaque reduction after six months of treatment will be reported in the current\
\ quarter potentially paving the way for phase testing ac immune said monday\
\ in its report of financial results for the first quarter of \n\n“we believe\
\ the maximum impact of aci can best be realized by partnering with takeda at\
\ this critical juncture in its development which will help us move rapidly into\
\ phase ” ac immune ceo andrea pfeifer said in a prepared statement “this agreement\
\ allows us to leverage the developmental expertise strategic vision and financial\
\ capacity of an accomplished organization that has demonstrated its ability to\
\ execute the type of comprehensive global program required for phase trials\
\ in alzheimer’s disease while allowing us to focus on completing phase b development\
\ and accelerating our efforts to replicate this success with enhanced funding\
\ for our earlystage pipeline”\n\nupdated to add the following three paragraphs\
\ with analyst commentary an antiamyloid beta or “abeta” approach already has\
\ partial validation from the fda approval of the amyloid plaque antibody busting\
\ drug leqemb from eisai as well as donanemab an eli lilly drug still under regulatory\
\ review leerink partners analyst marc goodman wrote in a march research note\
\ but safety could be a key differentiator for an alzheimer’s immunotherapy antibody\
\ drugs developed for the disease introduce the risk of amyloidrelating imaging\
\ abnormalities aria brain bleeding and swelling that is a known adverse effect\
\ of this class of therapies an earlier formulation of ac immune’s therapy yielded\
\ mixed phase data while the results showed favorable safety with no signs of\
\ aria the immune response was “suboptimal” goodman said\n\naci is a new formulation\
\ incorporating changes intended to boost the immune response goodman said translation\
\ of immune response to amyloid beta clearance andor clinical benefit remains\
\ a key question also active immunotherapy may take longer to show an effect compared\
\ with antibody drugs he added while those questions remain unanswered so far\
\ the takeda deal is positive news for ac immune goodman wrote in a monday research\
\ note\n\nsponsored post\n\n \n\n what’s keeping healthcare cios up at night how\
\ health systems automate routine phone calls to improve workforce effectiveness\
\ and reduce agent burnout\n\nwith hospitals struggling to retain staff and valuebased\
\ care shrinking healthcare revenues health systems must look to technology resources\
\ to become more efficient without losing sight of patient care or staff support\n\
\n“once again management has executed on a significant partnership with a big\
\ pharma company to develop an asset that has received minimal value in the stock\
\ confirming our longterm thesis that this management team can leverage its two\
\ proprietary drug discovery platforms and diversified pipeline to drive value”\
\ goodman said\n\nthe agreement makes ac immune eligible for up to billion in\
\ milestone payments which includes an option exercise fee in the lowtomidhundred\
\ millions of dollars according to the regulatory filing after exercising that\
\ option takeda will be responsible for clinical development of the alzheimer’s\
\ drug takeda will also handle regulatory submissions as well as commercialization\
\ if the drug is approved ac immune will receive royalties from takeda’s sales\
\ of the immunotherapy\n\naci would give takeda another opportunity to address\
\ alzheimer’s but with a drug candidate that has been derisked with clinical data\
\ the company previously partnered with denali therapeutics on the development\
\ of an antibody engineered to penetrate the brain to hit and activate a target\
\ called trem last august the two companies announced they would discontinue clinical\
\ development of this alzheimer’s drug after safety signals emerged in phase \
\ testing takeda also has a research collaboration with cure network dolby acceleration\
\ partners focused on developing small molecules that target tau in alzheimer’s\
\ and other brain disorders\n\nac immune has other alliances in alzheimer’s its\
\ antitau immunotherapy aci is currently in midstage clinical development under\
\ a partnership with johnson johnson subsidiary janssen pharmaceuticals a tau\
\ aggregation inhibitor is in preclinical development under a partnership with\
\ eli lilly two ac immune antibodies semorinemab and crenezumab were partnered\
\ with roche’s genentech division but after disappointing clinical trial results\
\ genentech terminated the alliance early this year returning to ac immune rights\
\ to both antibodies\n\npublic domain by flickr user scitechtrend\n\ntopics\n\
\n\n ac immune\n alzheimers disease\n clinical trials\n deals\n japan\n\
\ switzerland\n takeda pharmaceutical\n\nmedcity news daily newsletter\n\n\
\n sign up and get the latest news in your inbox\n\nenter your email address \
\ subscribe now\n\nwe will never sell or share your information without your consent\
\ see our privacy policy\n\nmore from medcity news\n\n\nmedcity influencers\n\n\
\ \n\n restoring public trust in the biopharma industry the role of advanced\
\ analytics\n\nby ryan calsbeek and haider nazar\n\nmedcity influencers\n\n \n\
\n the right to privacy — what a novel concept\n\nby chris bowen\n\nmedcity influencers\n\
\n \n\n patients want personalized digital experiences could a modular back end\
\ help\n\nby luiz cieslak\n\nhealth tech payers\n\n \n\n ncpa providers file lawsuit\
\ against uhg over change healthcare cyberattack\n\nby marissa plescia\n\n \n\n\
health it\n\n best practices in achieving revenue cycle excellence \n\ndiscover\
\ the best practices in revenue cycle management to enhance financial health and\
\ streamline administrative processes in healthcare\n\nby greenway health\n\n\
recommended\n\n\nsponsored post\n\n streamlining healthcare how technology is\
\ removing friction for providers\n\n annual benefit consultant report offers\
\ window into selfinsured employers’ benefit priorities including emphasis on\
\ care navigation\n\nsponsored post\n\n hospitals and health system executives\
\ say change management is essential for innovation\n\n \n\nsponsored content\n\
\n the impact brands empowering wellness through natural and holistic solutions\n\
\nin an era of escalating healthcare costs and a growing preference for natural\
\ holistic approaches to health the impact brands emerges as a collective of diverse\
\ brands dedicated to supporting overall wellness through natural means\n\nby\
\ impact brands\n\nmedcity news daily newsletter\n\n\n sign up and get the latest\
\ news in your inbox\n\nenter your email address subscribe now\n\nwe will never\
\ sell or share your information without your consent see our privacy policy\n\
\n advertise\n about\n newsletter\n\nour sites\n\n\n above the law\n\n\
\ how appealing\n\n breaking defense\n\n breaking energy\n\n breaking gov\n\
\n deal breaker\n\n fashionista\n\n med city news\n\n© breaking media inc\
\ all rights reserved registration or use of this site constitutes acceptance\
\ of our terms of service and privacy policy\n\n dmca compliant dmca compliance\
\ information for abovethelawcom\n\n \n\n \n\n×\n\nthis website uses cookies\
\ to enhance user experience and to analyze performance and traffic on our website\
\ we also share information about your use of our site with our social media advertising\
\ and analytics partners\n\ndo not sell my personal information accept cookies\n\
\n company logo\n\ndo not sell my personal information\n\n\nwhen you visit our\
\ website we store cookies on your browser to collect information the information\
\ collected might relate to you your preferences or your device and is mostly\
\ used to make the site work as you expect it to and to provide a more personalized\
\ web experience however you can choose not to allow certain types of cookies\
\ which may impact your experience of the site and the services we are able to\
\ offer click on the different category headings to find out more and change our\
\ default settings according to your preference you cannot optout of our first\
\ party strictly necessary cookies as they are deployed in order to ensure the\
\ proper functioning of our website such as prompting the cookie banner and remembering\
\ your settings to log into your account to redirect you when you log out etc\
\ for more information about the first and third party cookies used please follow\
\ this link \nmore information\n\nallow all\n\n manage consent preferences\n\n\
\ strictly necessary cookies\n\nalways active\n\nthese cookies are necessary for\
\ the website to function and cannot be switched off in our systems they are usually\
\ only set in response to actions made by you which amount to a request for services\
\ such as setting your privacy preferences logging in or filling in forms you\
\ can set your browser to block or alert you about these cookies but some parts\
\ of the site will not then work these cookies do not store any personally identifiable\
\ information\n\n sale of personal data\n\n sale of personal data\n\nunder the\
\ california consumer privacy act you have the right to optout of the sale of\
\ your personal information to third parties these cookies collect information\
\ for analytics and to personalize your experience with targeted ads you may exercise\
\ your right to opt out of the sale of personal information by using this toggle\
\ switch if you opt out we will not be able to offer you personalised ads and\
\ will not hand over your personal information to any third parties additionally\
\ you may contact our legal department for further clarification about your rights\
\ as a california consumer by using this exercise my rights link \n \nif you\
\ have enabled privacy controls on your browser such as a plugin we have to take\
\ that as a valid request to optout therefore we would not be able to track your\
\ activity through the web this may affect our ability to personalize ads according\
\ to your preferences\n\n performance cookies\n \n switch label label\n\
\ \n these cookies allow us to count visits and traffic sources so we can\
\ measure and improve the performance of our site they help us to know which pages\
\ are the most and least popular and see how visitors move around the site all\
\ information these cookies collect is aggregated and therefore anonymous if you\
\ do not allow these cookies we will not know when you have visited our site and\
\ will not be able to monitor its performance\n \n\n targeting cookies\n\
\ \n switch label label\n \n these cookies may be set through our\
\ site by our advertising partners they may be used by those companies to build\
\ a profile of your interests and show you relevant adverts on other sites they\
\ do not store directly personal information but are based on uniquely identifying\
\ your browser and internet device if you do not allow these cookies you will\
\ experience less targeted advertising\n \n\n cookie list\n\n \n\nclear\n\n\
\ checkbox label label\n\napply cancel\n\nconsent leginterest\n\n checkbox label\
\ label\n\n checkbox label label\n\n checkbox label label\n\nconfirm my choices\n\
\n powered by onetrust"
- text: "finanzennet seite nicht gefunden\n\n blob \n\ndax est msciw dow nas\
\ bitcoin euro öl gold \n\n finanzennet online broker online broker\n\nbeliebte\
\ suche\n\ndax ölpreis euro dollar bitcoin euro goldpreis\n\nmeistgesucht\n\
\ntesla acxt tesla zur watchlist hinzufügen nvidia nvidia zur watchlist hinzufügen\
\ varta atgj varta zur watchlist hinzufügen deutsche bank deutsche bank zur\
\ watchlist hinzufügen rheinmetall rheinmetall zur watchlist hinzufügen crowdstrike\
\ apkr crowdstrike zur watchlist hinzufügen alphabet a ex google ayf alphabet\
\ a ex google zur watchlist hinzufügen sap sap zur watchlist hinzufügen lvmh\
\ moet hennessy louis vuitton lvmh moet hennessy louis vuitton zur watchlist\
\ hinzufügen tui tuag tui zur watchlist hinzufügen porsche pag porsche zur watchlist\
\ hinzufügen amazon amazon zur watchlist hinzufügen apple apple zur watchlist\
\ hinzufügen bayer bay bayer zur watchlist hinzufügen nel asa ab nel asa zur\
\ watchlist hinzufügen\n\nalle aktien für euro zzgl spreads handeln mit finanzennet\
\ zero hier informieren\n\nheute im fokus\n\n uhr dax schließt klar im minus \
\ rheinmetallzahlen überzeugen porsche mit gewinnrückgang deutsche bank mit\
\ verlust tesla alphabet crowdstrike tmtg visa lvmh im fokus\n\ntop news\n\n\
\ uhr börse new york nasdaq zeigt sich leichter \n\n uhr schwache performance\
\ in new york sp notiert im minus \n\nsuche\n\nzero depot finanzennet zero\
\ depot finanzennet zero trading finanzennet zero zero depot finanzennet zero\
\ trading finanzennet zero krypto kaufen etfsparplan finanzennet oskar anmeldenanmelden\n\
\nfavoriten\n\n \n\nseite zu favoriten hinzufügen\n\n \n\nwird geladen \n\n\
\ \n\ngeben sie einen neuen namen \nfür diesen favoriten ein\n\n \n\nverwerfen\
\ speichern\n\nlogin\n\n \n\noder\n\n \n\nneu weiter mit google\n\n \n\nneu\
\ auf finanzennet\n\nkostenfrei registrieren und vorteile nutzen\n\n \n\nübersicht\
\ wertpapierdepots musterdepots watchlists meine news newsletter forum trading\
\ desk apps social media podcasts\n\n \n\nprofil\n\nübersicht wertpapierdepots\
\ musterdepots watchlists meine news newsletter forum trading desk apps social\
\ media podcasts\n\n \n\nprofil logout\n\n depot eröffnen depot eröffnen\n\
\ zerotrading zerotrading\n etfsparplan etfsparplan\n login login\n \
\ übersicht\n wertpapierdepots\n musterdepots\n watchlists\n\
\ meine news\n newsletter\n forum\n trading desk\n \
\ apps\n social media\n podcasts\n profil\n logout\n\
\n aktien\n aktienübersicht\n aktiensuche\n meistgesuchte\
\ aktien\n top flop dax\n top deutschland\n top\
\ ausland\n branchen\n ipos neuemissionen\n chartanalyse\n\
\ specials\n advertorials\n pennystocks\n \
\ videos\n trading desk\n realtimekurse\n daxaktien\n\
\ mdaxaktien\n sdaxaktien\n tecdaxaktien\n \
\ dow jonesaktien\n euro stoxx aktien\n smiaktien\n \
\ atxaktien\n weitere aktien deutschland\n weitere\
\ aktien usa\n termine\n übersicht der termine\n hauptversammlung\n\
\ quartalszahlen\n wirtschaftskalender\n dividendenausschüttung\n\
\ insiderdaten\n anlagetrends\n kiaktien\n \
\ drohnen\n chatgpt profiteure\n cannabismarihuana\n \
\ solaraktien\n gamingaktien\n vermögenswirksame leistungen\n\
\ trading idee\n finanzennet watchlists neu\n dividenden\n\
\ top dividendenrendite\n dividendentermine\n brokervergleich\n\
\ onlinebrokervergleich\n cfdbrokervergleich\n roboadvisorvergleich\n\
\ kryptobrokervergleich\n kryptobörsenvergleich\n aktienratgeber\n\
\ aktien kaufen verkaufen\n aktienhandel mit system\n \
\ aktien als geschenk\n selection\n deutschlands bestes\
\ girokonto mit zinsen pa neu\n \n news\n newsübersicht\n \
\ unternehmensmeldungen\n heute im fokus\n expertenkolumnen\n\
\ nachrichten aus deutschland\n nachrichten aus usa\n \
\ nachrichten weitere länder\n news standardwerte\n \
\ news nebenwerte\n konjunkturdaten\n webinare\n \
\ kursbewegungen\n videos\n newsletter\n newssuche\n\
\ aktiennews\n anleihennews\n cfdnews\n \
\ devisennews\n etfnews\n fondsnews\n geld karriere\
\ lifestyle\n private finanzennews\n rohstoffenews\n \
\ zertifikatenews\n zinsennews\n kryptowährungennews\n\
\ news zu nachhaltigkeit\n indexnews\n daxnews\n \
\ dow jonesnews\n mdaxnews\n eurostoxxnews\n \
\ tecdaxnews\n nasdaqnews\n sp news\n atxnews\n\
\ sminews\n nikkei news\n analysen\n daxanalysen\n\
\ analysen nach indizes\n chartanalyse\n analysen\
\ nach ländern\n zum researchtool\n rubriken\n redaktion\
\ finanzennet\n aktie im fokus\n adhocmeldungen\n \
\ investoren news\n themen\n toprankings\n expertenempfehlung\
\ zum verkauf\n expertenempfehlung zum kauf\n topnews\n \
\ \n table classtabletbody classtabletbodytr classtabletrtd classtabletd\
\ paddingverticala classdisplayblock marginbottom hrefnachrichtaktienboersenewyorknasdaqzeigtsichleichterimg\
\ classimg imgstretch src width height alt loadinglazy aspana hrefnachrichtaktienboersenewyorknasdaqzeigtsichleichterbörse\
\ new york nasdaq zeigt sich leichteraspantdtrtr classtabletrtd classtabletd\
\ paddingverticalspana hrefnachrichtaktienschwacheperformanceinnewyorkspnotiertimminusschwache\
\ performance in new york sampp notiert im minusaspantdtrtr classtabletrtd classtabletd\
\ paddingverticalspana hrefnachrichtaktienboersenewyorkinrotdowjonesinderverlustzonebörse\
\ new york in rot dow jones in der verlustzoneaspantdtrtr classtabletrtd classtabletd\
\ paddingverticalspana hrefnachrichtaktienschwacheperformanceinnewyorknasdaqcompositeammittwochmittagleichterschwache\
\ performance in new york nasdaq composite am mittwochmittag leichteraspantdtrtr\
\ classtabletrtd classtabletd paddingverticalspana hrefnachrichtaktienguccimutterkeringmeldetumsatzundgewinnrueckgangimerstenhalbjahrkering\
\ meldet umsatz und gewinnrückgang im ersten halbjahraspantdtrtbodytable\n \
\ \n alle topnews\n indizes\n indexübersicht\n weltindizes\n\
\ chartübersicht\n länder\n emerging markets\n \
\ futures\n märkte\n börsenfeiertage\n wichtige\
\ indizes\n dax\n mdax\n sdax\n tecdax\n\
\ dow jones\n sp \n nasdaq \n euro stoxx\
\ \n smi\n atx\n cac \n nikkei \n \
\ index listen\n dax\n mdax\n sdax\n \
\ tecdax\n dow jones\n sp \n nasdaq \n \
\ eurostoxx\n smi\n atx\n cac \n nikkei\
\ \n topflop listen\n dax\n mdax\n sdax\n\
\ tecdax\n eurostoxx\n smi\n atx\n \
\ sp \n dow jones\n nasdaq \n cac \n \
\ realtimekurse\n realtimeübersicht\n daxrealtime\n \
\ tecdaxrealtime\n mdaxrealtime\n euro stoxx realtime\n\
\ dow jones realtime\n nasdaq realtime\n sp realtime\n\
\ nikkei realtime\n atxrealtime\n fonds\n fondsübersicht\n\
\ topperformer\n fondsgesellschaften\n nachhaltige\
\ investments\n anlagedepot neu\n fondssuche\n aktienfonds\n\
\ rentenfonds\n immobilienfonds\n geldmarktfonds\n\
\ rohstofffonds\n mischfonds\n sonstige fonds\n\
\ nachhaltige fonds\n fondsregionen\n fonds deutschland\n\
\ fonds europa\n fonds usa\n fonds welt\n \
\ fonds news\n interviews\n hedgefonds\n kvgnews\n\
\ nachhaltige investments\n fonds mit fngsiegel\n geldanlage\
\ mit ökofonds\n specials\n german fund champions \n \n\
\ etfs\n etfübersicht\n topperformer etfs\n etfnews\n\
\ etfkursbewegungen\n etflexikon\n etcübersicht\n\
\ anlagedepot neu\n etfsuche\n msci worldetfs\n \
\ daxetfs\n aktienetfs\n anleihenetfs\n rohstoffetfs\n\
\ geldmarktetfs\n etfsparplan\n beste sparpläne tipps\
\ tricks\n beliebte sparplanetfs\n etfsparplanvergleich\n\
\ etfratgeber\n etf kaufen\n daxetfs im test\n \
\ mdaxetfs im test\n msci worldetfs im test\n goldetfs\
\ kaufen\n roboadvisorvergleich\n roboadvisor im test\n \
\ investieren mit oskar\n geldanlage für kinder\n etfsparen\
\ für kinder\n börsenspielvergleich\n specials\n wissenswertes\
\ über etfs\n etfs intelligent handeln\n german fund champions\
\ \n \n zertifikate\n zertifikateübersicht\n topbasiswerte\n\
\ top zertifikate umsätze\n produktnews\n news von\
\ emittenten\n emittenten\n video produkterklärungen\n \
\ derivate newsletter\n tradingdepot\n zertifikatesuche\n\
\ airbagzertifikate\n aktienanleihen\n alphazertifikate\n\
\ basketzertifikate\n bonuszertifikate\n discountzertifikate\n\
\ expresszertifikate\n index trackerzertifikate\n \
\ garantiezertifikate\n outperformancezertifikate\n sprintzertifikate\n\
\ kioptimierte hebelproduktsuche beta\n tools\n zertifikatematrix\n\
\ emittentenmatrix\n knockoutmap\n top aktienanleihen\n\
\ top bonuszertifikate\n top discountzertifikate\n basiswertsuche\n\
\ indizes\n aktien\n baskets\n währungen\n\
\ rohstoffe\n zinsen anleihen\n sonstige basiswerte\n\
\ wissen\n aktienanleihen\n bonuszertifikate\n \
\ discountzertifikate\n expresszertifikate\n garantiezertifikate\n\
\ goldzertifikate\n indexzertifikate\n outperformancezertifikate\n\
\ ölzertifikate\n rollingdiscountzertifikate\n twinwinzertifikate\n\
\ neuemissionen\n letzte neuemissionen\n intradayemissionen\n\
\ discountzertifikate\n bonuszertifikate\n sonstige\n\
\ specials\n zertifikate\n aktienanleihen\n \
\ rohstoffe\n \n hebelprodukte\n hebelprodukteübersicht\n \
\ meistgeklickte basiswerte\n os mit top trades\n \
\ ko mit top trades\n emittenten\n produktnews\n \
\ news von emittenten\n derivate newsletter\n tradingdepot\n\
\ hebelproduktesuche\n optionsscheine\n knockoutzertifikate\n\
\ inlineoptionsscheine\n exotische optionsscheine\n \
\ faktoroptionsscheine\n kioptimierte hebelproduktsuche beta\n \
\ tools\n zertifikatematrix\n emittentenmatrix\n \
\ knockoutmap\n top aktienanleihen\n top bonuszertifikate\n\
\ top discountzertifikate\n basiswertsuche\n indizes\n\
\ aktien\n baskets\n währungen\n rohstoffe\n\
\ zinsen anleihen\n sonstige basiswerte\n wissen\n\
\ faktoroptionsscheine\n goldzertifikate\n hebelzertifikate\n\
\ knockoutzertifikate\n mini futures\n optionsscheine\n\
\ ölzertifikate\n turbozertifikate\n neuemissionen\n\
\ letzte neuemissionen\n intradayneuemissionen\n \
\ optionsscheine\n knockouts\n specials\n zertifikate\n\
\ aktienanleihen\n rohstoffe\n cfds\n was\
\ sind cfds\n volatile trading instrumente\n cfd brokervergleich\n\
\ \n anleihen\n anleihenübersicht\n top performer\n \
\ meistgesuchte anleihen\n neuemissionen\n anleiheemittenten\n\
\ anleihenrating\n anleihensuche\n europäische staatsanleihen\n\
\ unternehmensanleihen\n bundesanleihen\n usstaatsanleihen\n\
\ anleihen mit aaarating\n investmentgrade anleihen\n \
\ junk bonds high yield\n rendite über \n zerobonds\n\
\ wissen\n bundesanleihen\n emerging marketsanleihen\n\
\ eurostaatsanleihen\n genussscheine\n jumbo pfandbriefe\n\
\ währungsanleihen\n unternehmensanleihen\n niedrigzinsanleihen\n\
\ anleihen mit variablem zins\n weitere anleihetypen\n \
\ sonderformen\n zinsen\n zinsstrukturkurven\n \
\ leitzins\n libor\n euribor\n zinstermine\n \
\ historische leitzinsen\n leitzins news\n anleihenratgeber\n\
\ anleihen kaufen\n \n rohstoffe\n rohstoffeübersicht\n\
\ realtimekurse\n rohstoffcharts\n basiswissen\n\
\ rohstoffzertifikate\n wichtige rohstoffe\n gold\n\
\ silber\n ölpreis\n platin\n palladium\n\
\ weizen\n aluminium\n erdgas\n gold kaufen\n\
\ so funktioniert der goldkauf\n goldmünzen kaufen\n \
\ goldbarren kaufen\n american eagle\n britannia\n \
\ krügerrand\n maple leaf\n silber kaufen\n \
\ so funktioniert der silberkauf\n silbermünzen kaufen\n silberbarren\
\ kaufen\n forward curve\n edelmetalle\n energierohstoffe\n\
\ industriemetalle\n agrarrohstoffe\n etcs\n \
\ einzelner rohstoff\n rohstoffkörbe\n specials\n \
\ rohstoffe\n cfds\n was sind cfds\n cfdbrokervergleich\n\
\ \n krypto\n kryptoübersicht\n kryptonews\n \
\ kryptotrading tipp\n wichtige kryptowährungen\n bitcoin kurs\n\
\ ethereum kurs\n tether kurs\n binance coin kurs\n\
\ monero kurs\n ripple kurs\n avalanche kurs\n \
\ cardano kurs\n uniswap kurs\n polygon kurs\n \
\ litecoin kurs\n solana kurs\n polkadot kurs\n \
\ chainlink kurs\n kryptowährungen kaufen\n bitcoin kaufen\n\
\ ethereum kaufen\n tether kaufen\n bitcoin cash\
\ kaufen\n monero kaufen\n ripple kaufen\n avalanche\
\ kaufen\n cardano kaufen\n uniswap kaufen\n polygon\
\ kaufen\n litecoin kaufen\n solana kaufen\n polkadot\
\ kaufen\n chainlink kaufen\n kryptoratgeber\n kryptobörsenvergleich\n\
\ kryptobrokervergleich\n investieren in die blockchain\n\
\ bitcoin steuern\n nft kaufen\n nftetf kaufen\n\
\ cfds\n was sind cfds\n cfdbrokervergleich\n \
\ \n devisen\n devisenübersicht\n realtimekurse\n \
\ crossrates\n tipps zum devisenhandel\n wichtige devisenpaare\n\
\ eurodollar\n eurofranken\n europfund\n \
\ türkische lira\n eurozloty\n eurorussische rubel\n \
\ eurobaht\n eurotschechische krone\n währungsrechner\n\
\ eurofranken\n eurodollar\n europfund\n \
\ eurotürkische lira\n eurozloty\n eurorussische rubel\n\
\ eurobaht\n eurotschechische krone\n kryptowährungen\n\
\ bitcoin\n ethereum\n ripple\n bitcoin\
\ cash\n litecoin\n iota\n diem\n neo\n\
\ kryptobroker vergleich\n bitcoin kaufen\n bitcoin\
\ cash kaufen\n diem kaufen\n ethereum kaufen\n \
\ iota kaufen\n neo kaufen\n kryptobörsen vergleich\n \
\ kryptowährungshandel\n ratgeber kryptowährungen\n cfds\n \
\ was sind cfds\n cfdbrokervergleich\n \n ratgeber\n\
\ unsere empfehlungen\n top unternehmen\n brutto netto\
\ rechner\n etfsparplan\n msci worldetf\n aktien\
\ kaufen\n cfdhandel\n cannabisaktien kaufen\n forextrading\n\
\ small caps\n geldanlage\n onlinedepot eröffnen\n \
\ geldanlage\n sparen für kinder\n öl handeln\n \
\ fonds kaufen\n anleihen kaufen\n optionsscheine\n\
\ kupfer kaufen\n gold kaufen\n goldshop\n \
\ etfs fonds und zertifikate\n etfs kaufen\n dow jonesetfs\n\
\ goldetfs\n dividendenfonds\n knockoutzertifikate\n\
\ goldzertifikate\n faktoroptionsscheine\n alternative\
\ investments\n kryptowährungen\n bitcoin kaufen\n ethereum\
\ kaufen\n ripple kaufen\n diem kaufen\n kryptobrokervergleich\n\
\ kryptobörsenvergleich\n konto kredit\n tagesgeldvergleich\n\
\ festgeldvergleich\n kreditkartenvergleich\n ratenkredit\n\
\ girokontovergleich\n onlinebanking\n broker depots\n\
\ roboadvisorvergleich\n onlinebrokervergleich\n \
\ oskar im test\n versicherung vorsorge\n kfzversicherung\n\
\ haftpflichtversicherung\n hausratversicherung\n \
\ riesterrente\n vermögenswirksame leistungen\n betriebsrente\n\
\ youtube\n etfsparplan einfach erklärt\n etfauswahl\n\
\ aktien kaufen in schritten\n die größten fehler beim aktienkauf\n\
\ geldanlagetipps\n \n\nsuche\n\nbeliebte suche\n\ndax ölpreis\
\ euro dollar bitcoin euro goldpreis\n\nmeistgesucht\n\ntesla acxt tesla zur\
\ watchlist hinzufügen nvidia nvidia zur watchlist hinzufügen varta atgj varta\
\ zur watchlist hinzufügen deutsche bank deutsche bank zur watchlist hinzufügen\
\ rheinmetall rheinmetall zur watchlist hinzufügen crowdstrike apkr crowdstrike\
\ zur watchlist hinzufügen alphabet a ex google ayf alphabet a ex google zur\
\ watchlist hinzufügen sap sap zur watchlist hinzufügen lvmh moet hennessy louis\
\ vuitton lvmh moet hennessy louis vuitton zur watchlist hinzufügen tui tuag\
\ tui zur watchlist hinzufügen porsche pag porsche zur watchlist hinzufügen\
\ amazon amazon zur watchlist hinzufügen apple apple zur watchlist hinzufügen\
\ bayer bay bayer zur watchlist hinzufügen nel asa ab nel asa zur watchlist hinzufügen\n\
\nalle aktien für euro zzgl spreads handeln mit finanzennet zero hier informieren\n\
\nsuche\n\n home home\n aktien aktien\n perseus therapeutics announces development\
\ of tslp antibody for prevention of hair loss in cancer patients and treatment\
\ of inflammatory diseases with wellknown cro partner\n\nperseus therapeutics\
\ announces development of tslp antibody for prevention of hair loss in cancer\
\ patients and treatment of inflammatory diseases with wellknown cro partner\n\
\n\n uhr\n\n \n\nwerbung\n\nnew york may prnewswire perseus therapeutics\
\ a pioneering biopharmaceutical company based in new york city is proud to announce\
\ the development of a novel thymic stromal lymphopoietin tslp antibody aimed\
\ at preventing hair loss in cancer patients and treating a range of inflammatory\
\ diseases including asthma\n\n pegasus horse next to the words perseus therapeutics\
\ inc\n\ntslp antibodies have recently gained significant attention in the medical\
\ and pharmaceutical communities these antibodies have shown potential in addressing\
\ various inflammatory and allergic conditions driven by their promising efficacy\
\ data and the unmet medical needs they aim to fulfill\n\nseveral companies and\
\ research groups are actively exploring tslp antibodies with notable developments\
\ including\n\n astrazeneca and amgen have developed tezepelumab the firstinclass\
\ antitslp monoclonal antibody approved for severe asthma treatment\n johnson\
\ johnson acquired proteologix to access its bispecific antibody targeting tslp\
\ and il\n blackstone has launched uniquity to advance mercks phase high potency\
\ tslp antibody\n innovent biologics is conducting a phase i study on ibi a\
\ dualfunction antibody targeting both ilrα and tslp\n sanofi and regeneron\
\ are developing sar a novel biologic targeting both tslp and il for asthma\n\
\ teva pharmaceuticals and biolojic design have entered into an exclusive license\
\ agreement to develop bispecific antibodies targeting tslp and il\n gsk recently\
\ acquired aiolos bio for billion upfront to enhance its respiratory biologics\
\ portfolio with aio a phase longacting antitslp monoclonal antibody\n\nthese\
\ strategic moves underscore the growing interest in tslp antibodies for treating\
\ a wide range of inflammatory and allergic conditions perseus therapeutics is\
\ poised to contribute to this dynamic field with its innovative approach to preventing\
\ hair loss in cancer patients a common and distressing side effect of cancer\
\ treatments and addressing other inflammatory diseases\n\nperseus therapeutics\
\ is committed to advancing the science of tslp antibodies to meet critical unmet\
\ medical needs said joseph hernandez chairman and founder of perseus therapeutics\
\ our work aims not only to improve the quality of life for cancer patients by\
\ preventing hair loss but also to provide effective treatments for various inflammatory\
\ conditions\n\nfor more information about perseus therapeutics and its pipeline\
\ of innovative therapies please visit or contact filecconvertwordtohtmlprimarycontentdownloadpath\n\
\nabout perseus therapeutics inc \nperseus therapeutics is a duke university\
\ spinout biopharmaceutical company dedicated to developing innovative therapies\
\ for cancer patients and those suffering from inflammatory diseases based in\
\ new york city perseus therapeutics is at the forefront of antibody research\
\ and development striving to bring new hope and improved outcomes to patients\
\ worldwide\n\n cision view original content to download multimedia\n\nsource\
\ perseus therapeutics inc\n\netf und aktiensparpläne ohne ordergebühren zzgl\
\ spreads\n\nin eigener sache\n\nvermögensaufbau mit sparplänen kann so einfach\
\ sein wechsle zu finanzennet zero und zahle ab sofort keine ordergebühren mehr\
\ nur marktübliche spreads\n\ninformiere dich jetzt und nutze zerokonditionen\
\ für deine sparpläne\n\n \n\ndas könnte sie auch interessieren\n\nempfohlen von\
\ \n\nnewssuche\n\n\nsuche\n\nwerbung\n\n tradingnews\n\ntable classtabletbody\
\ classtabletbodytr classtabletrtd classtabletd paddinghorizontaldiv classlogohvb\
\ titleunicredit bank agdivtdtd classtabletd tabletdlineclampa href targetblank\
\ relnofollow noopener titletagesausblick für anleger reagieren enttäuscht auf\
\ techzahlen ifo nordex und usarbeitsmarktdaten stehen antagesausblick für anleger\
\ reagieren enttäuscht auf techzahlen ifo nordex und usarbeitsmarktdaten stehen\
\ anatdtrtr classtabletrtd classtabletd paddinghorizontaldiv classlogosocgen titlesociete\
\ generaledivtdtd classtabletd tabletdlineclampa href targetblank relnofollow\
\ noopener titlemehr diversifikation mit gleichgewichteten indizesmehr diversifikation\
\ mit gleichgewichteten indizesatdtrtr classtabletrtd classtabletd paddinghorizontaldiv\
\ classlogohsbc titlehsbcdivtdtd classtabletd tabletdlineclampa href targetblank\
\ relnofollow noopener titlealphabettochter google steigert werbeerlöse – aktie\
\ dennoch deutlich im minusalphabettochter google steigert werbeerlöse – aktie\
\ dennoch deutlich im minusatdtrtr classtabletrtd classtabletd paddinghorizontaldiv\
\ classlogoxtb titlextb xtrade brokersdivtdtd classtabletd tabletdlineclampa href\
\ targetblank relnofollow noopener titletradingidee des tages silver tradingidee\
\ des tages silver atdtrtr classtabletrtd classtabletd paddinghorizontaldiv classlogoubs\
\ titleubsdivtdtd classtabletd tabletdlineclampa href targetblank relnofollow\
\ noopener titlesap se – neues allzeithochsap se – neues allzeithochatdtrtr classtabletrtd\
\ classtabletd paddinghorizontaldiv classlogowhs titlewh selfinvestdivtdtd classtabletd\
\ tabletdlineclampa href targetblank relnofollow noopener titlebullische fortsetzung\
\ im goldfuture möglichbullische fortsetzung im goldfuture möglichatdtrtr classtabletrtd\
\ classtabletd paddinghorizontaldiv classlogowgz titledz bankdivtdtd classtabletd\
\ tabletdlineclampa href targetblank relnofollow noopener titledax gd und slow\
\ stochastik liefern kaufsignaledax gd und slow stochastik liefern kaufsignaleatdtrtbodytable\n\
\nalle tradingnews alle tradingnews\n\nwerbung\n\n investmentnews\n\ntable classtabletbody\
\ classtabletbodytr classtabletrtd classtabletddiv classlogowikifolio titlewikifoliodivtdtd\
\ classtabletd tabletdlineclampa href targetblank relnofollow noopener titlebyebye\
\ big tech hello small capsbyebye big tech hello small capsatdtrtr classtabletrtd\
\ classtabletddiv classlogobitcapfavico titlebit capitaldivtdtd classtabletd tabletdlineclampa\
\ href targetblank relnofollow noopener titlebit capital welche techaktien sind\
\ gerade wirklich günstigbit capital welche techaktien sind gerade wirklich günstigatdtrtr\
\ classtabletrtd classtabletddiv classlogofvsfavico titleflossbach von storchdivtdtd\
\ classtabletd tabletdlineclampa href targetblank relnofollow noopener titlemultiasset\
\ auf den abgesang folgt das comebackmultiasset auf den abgesang folgt das comebackatdtrtr\
\ classtabletrtd classtabletddiv classlogoetcgroup titleetc groupdivtdtd classtabletd\
\ tabletdlineclampa href targetblank relnofollow noopener titlebitcoin schießt\
\ inmitten eines globalen itausfalls in die höhe etc group crypto market compass\
\ juli bitcoin schießt inmitten eines globalen itausfalls in die höhe etc group\
\ crypto market compass juli atdtrtr classtabletrtd classtabletddiv classlogoetoro\
\ titleetorodivtdtd classtabletd tabletdlineclampa hrefnachrichtaktienmonetarisierungvonkidasgrossepotenzialunddiehohenerwartungen\
\ titlemonetarisierung von ki das große potenzial und die hohen erwartungenmonetarisierung\
\ von ki das große potenzial und die hohen erwartungenatdtrtr classtabletrtd classtabletddiv\
\ classlogoophirum titleophirumdivtdtd classtabletd tabletdlineclampa href targetblank\
\ relnofollow noopener titlegoldsparpläne sind immer eine gute wahl jetzt mehr\
\ denn jegoldsparpläne sind immer eine gute wahl jetzt mehr denn jeatdtrtr classtabletrtd\
\ classtabletddiv classlogozerofavico titlezerodivtdtd classtabletd tabletdlineclampa\
\ href targetblank relnofollow noopener titlekryptos handeln bei finanzennet\
\ zerokryptos handeln bei finanzennet zeroatdtrtr classtabletrtd classtabletddiv\
\ classlogowiwinfavico titlewiwindivtdtd classtabletd tabletdlineclampa href targetblank\
\ relnofollow noopener titlejetzt in elektromobilität investieren und p a maximal\
\ erwartete rendite sichernjetzt in elektromobilität investieren und p a maximal\
\ erwartete rendite sichernatdtrtr classtabletrtd classtabletddiv classlogodda\
\ titledeutsche digital assetsdivtdtd classtabletd tabletdlineclampa href targetblank\
\ relnofollow noopener titlevon den top krypto assets in einem etp profitieren\
\ dda crypto select etpvon den top krypto assets in einem etp profitieren dda\
\ crypto select etpatdtrtr classtabletrtd classtabletddiv classlogooskarfavico\
\ titleoskardivtdtd classtabletd tabletdlineclampa href titledieses geldgeschenk\
\ bringt ihnen bis zu eurodieses geldgeschenk bringt ihnen bis zu euroatdtrtbodytable\n\
\nalle investmentnews alle investmentnews\n\nwerbung\n\n terminhighlights\n\n\
teilnehmenthomas vittnerwie ich endlich beim trading erfolgreich wurde\n\nteilnehmenroland\
\ jegenneue volumenfeatures effektiv in den usmärkten nutzen\n\nteilnehmenmarcel\
\ ruthwarum jetzt die richtige zeit ist ein depot bei wh selfinvest zu eröffnen\n\
\nwerbung\n\nneue funktionen als erstes nutzen\n\nsie nutzen finanzennet regelmäßig\
\ dann nutzen sie jetzt neue funktionen als erstes\n\nhier informieren hier informieren\n\
\n börse stuttgart anlegerclub\n\n \n\n entdecke die app die deine finanzen\
\ revolutioniert – jetzt tradespot herunterladen die app die deine finanzen revolutioniert\
\ – jetzt tradespot herunterladen\n\n\n\nnews von die welt\n\ntable classtabletbody\
\ classtabletbodytr classtabletrtd classtabletda href targetblank relnofollow\
\ noopeneralphabets youtubeproblem und der wasserstoffschaufelherstelleratdtrtr\
\ classtabletrtd classtabletda href targetblank relnofollow noopener„wir bauen\
\ den leerstand von morgen“ – was ist an der mahnung dranatdtrtr classtabletrtd\
\ classtabletda href targetblank relnofollow noopenerrüstungsaktien kaufen – tipps\
\ für anfängeratdtrtr classtabletrtd classtabletda href targetblank relnofollow\
\ noopenerteslas elonmuskproblem und der erste kigesteuerte etfatdtrtr classtabletrtd\
\ classtabletda href targetblank relnofollow noopenerbis zu prozent kurspotenzial\
\ – mit diesen aktien profitieren sie von einem harrissiegatdtrtbodytable\n\n\
heute im fokus\n\n\ndax schließt klar im minus rheinmetallzahlen überzeugen \
\ porsche mit gewinnrückgang deutsche bank mit verlust tesla alphabet crowdstrike\
\ tmtg visa lvmh im fokus erhöht prognose hochtief steigert erneut gewinn deutlich\
\ apple kurszielanhebung durch jpmorgan tmobilekonkurrent att gewinnt hunderttausende\
\ neukunden texas instruments beruhigt mit ausblick umsatz und gewinnanstieg\
\ erwartet aireuropakauf durch iag eu bleibt skeptisch totalenergies investiert\
\ in rwewindpark in den niederlanden\n\nnachrichten\n\n\naktien\n\nalle\n\nroundup\
\ berlin und london wollen militärzusammenarbeit vertiefen\n\nwdhaktien wien schluss\
\ atx marginal im minus\n\naktien wien schluss atx im minus rhi nach zahlen\
\ schwach\n\nrenault so profitabel wie noch nie\n\nrady childrens hospital teamsters\
\ end ulp strike demand hospital return to negotiations\n\nsecond quarter turnover\
\ \n\nausblick ford motor öffnet die bücher zum abgelaufenen quartal\n\neqscms\
\ bp plc release of a capital market information\n\ntoprankings\n\n\ntable classtabletbody\
\ classtabletbodytr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg\
\ src width height titlemdax gewinner und verlierer die top flop aktien in kw\
\ alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongmdax\
\ gewinner und verlierer die top flop aktien in kw strongadiv classmarginverticalwelche\
\ aktie macht das rennendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton\
\ buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklickenadivtdtrtr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg\
\ src width height titletecdax gewinner und verlierer die top flop aktien in kw\
\ alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongtecdax\
\ gewinner und verlierer die top flop aktien in kw strongadiv classmarginverticalwelche\
\ aktie macht das rennendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton\
\ buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklickenadivtdtrtr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg\
\ src width height titledax gewinner und verlierer die top flop aktien in kw \
\ alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongdax\
\ gewinner und verlierer die top flop aktien in kw strongadiv classmarginverticalwelche\
\ aktie macht das rennendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton\
\ buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklickenadivtdtrtbodytable\n\nmehr mehr\n\ndie beliebtesten toprankings\n\
\n\ntable classtabletbody classtabletbodytr classtabletrtd classtabletd paddinghorizontala\
\ hreftoprankingtoprankingdetailaspinrankingimg src width height titlerohstoffpreise\
\ entwicklung gewinner und verlierer in q alt loadinglazyatdtd classtabletda\
\ hreftoprankingtoprankingdetailaspinrankingstrongrohstoffpreise entwicklung gewinner\
\ und verlierer in q strongadiv classmarginverticalwelcher rohstoff macht das\
\ rennendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton\
\ buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklickenadivtdtrtr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg\
\ src width height titledax gewinner und verlierer die top flop aktien im juni\
\ alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongdax\
\ gewinner und verlierer die top flop aktien im juni strongadiv classmarginverticalwelche\
\ aktie macht das rennendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton\
\ buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklickenadivtdtrtr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg\
\ src width height titlediese aktien hat warren buffett in den vergangenen monaten\
\ gekauft alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongdiese\
\ aktien hat warren buffett in den vergangenen monaten gekauftstrongadiv classmarginverticalwo\
\ hat der starinvestor zugeschlagendivdiva classdisplaynonemd fontwhitespacenowrapmd\
\ hreftoprankingtoprankingdetailaspinrankingjetzt durchklicken span classicon\
\ iconarrowdoubleright iconscalespanaa classbutton buttonstretchmd displaynone\
\ displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklickenadivtdtrtr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg\
\ src width height titledax gewinner und verlierer die top flop aktien im mai\
\ alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongdax\
\ gewinner und verlierer die top flop aktien im mai strongadiv classmarginverticalwelche\
\ aktie macht das rennendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton\
\ buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklickenadivtdtrtr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg\
\ src width height titlediese aktien befanden sich im ersten quartal im depot\
\ von bridgewater associates alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongdiese\
\ aktien befanden sich im ersten quartal im depot von bridgewater associatesstrongadiv\
\ classmarginverticalportfolioüberblickdivdiva classdisplaynonemd fontwhitespacenowrapmd\
\ hreftoprankingtoprankingdetailaspinrankingjetzt durchklicken span classicon\
\ iconarrowdoubleright iconscalespanaa classbutton buttonstretchmd displaynone\
\ displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt\
\ durchklickenadivtdtrtbodytable\n\nmehr top rankings mehr top rankings\n\numfrage\n\
\n\nsorgen sie sich um folgen der künstlichen intelligenz\n\nja\n\nnein\n\nabstimmen\n\
\ndirekt zu den ergebnissen direkt zu den ergebnissen\n\nquicklinks\n\n\ntable\
\ classtabletbody classtabletbodytr classtabletrtd classtabletda hrefaktienkurseaktienkurseatdtd\
\ classtabletda hrefboersenkursebeliebteste aktienatdtrtr classtabletrtd classtabletda\
\ hrefaktiendaxrealtimekurserealtimekurseatdtd classtabletda hrefindizesalle indizesatdtrtr\
\ classtabletrtd classtabletda hreftoptop atdtd classtabletda hrefindexdaxtopfloptopsflopsatdtrtr\
\ classtabletrtd classtabletda hrefinsiderdateninsiderdatenatdtd classtabletda\
\ hrefaktiendividendendividendenatdtrtr classtabletrtd classtabletda hrefprofiluebersichtportfolioatdtd\
\ classtabletdtdtrtbodytable\n\n \n\n finanzennet zero badge\n\naktien kaufen\
\ zu topkonditionen\n\naktien etfs derivate kryptos und mehr jetzt für euro\
\ pro trade handeln zzgl marktüblicher spreads\n\njetzt informieren\n\n finanzennet\
\ zero\n\njetzt informieren\n\n oskar app\n\nder einfache und intelligente etfsparplan\n\
\noskar ist der einfache und intelligente etfsparplan er übernimmt die etfauswahl\
\ ist steuersmart transparent und kostengünstig\n\njetzt mehr erfahren\n\n oskar\n\
\njetzt mehr erfahren\n\naktien news quick links\n\nbörsennews börsennewsaktien\
\ news aktien newsfinanznachrichten finanznachrichtendax news dax newsmdax news\
\ mdax newstecdax news tecdax newsdow jones news dow jones newsnasdaq news nasdaq\
\ newsdevisen news devisen newsdollar news dollar newseuro news euro newskryptowährungen\
\ news kryptowährungen newsbitcoin news bitcoin newsnvidia aktie news nvidia aktie\
\ newsrheinmetall aktie news rheinmetall aktie newstesla aktie news tesla aktie\
\ newsbasf aktie news basf aktie newsbayer aktie news bayer aktie newsamazon aktie\
\ news amazon aktie newssiemens energy aktie news siemens energy aktie newstui\
\ aktie news tui aktie newsallianz aktie news allianz aktie newsmicrosoft aktie\
\ news microsoft aktie newssap aktie news sap aktie newsdeutsche bank aktie news\
\ deutsche bank aktie newsapple aktie news apple aktie newscommerzbank aktie news\
\ commerzbank aktie newsplug power aktie news plug power aktie newshensoldt aktie\
\ news hensoldt aktie newsinfineon aktie news infineon aktie newspaypal aktie\
\ news paypal aktie newsrwe aktie news rwe aktie newsrenk aktie news renk aktie\
\ newslufthansa aktie news lufthansa aktie newsairbus aktie news airbus aktie\
\ newsbyd aktie news byd aktie newsbiontech aktie news biontech aktie newsthyssenkrupp\
\ aktie news thyssenkrupp aktie newsmercedes aktie news mercedes aktie newsnordex\
\ aktie news nordex aktie newsvonovia aktie news vonovia aktie newsamd aktie news\
\ amd aktie newsuniper aktie news uniper aktie newsevotec aktie news evotec aktie\
\ newsmorphosys aktie news morphosys aktie newsnovo nordisk aktie news novo nordisk\
\ aktie newspfizer aktie news pfizer aktie newsintel aktie news intel aktie newspalantir\
\ aktie news palantir aktie newscovestro aktie news covestro aktie newssiemens\
\ aktie news siemens aktie newscurevac aktie news curevac aktie newspuma aktie\
\ news puma aktie newsadidas aktie news adidas aktie newsnel aktie news nel aktie\
\ newsdaimler truck aktie news daimler truck aktie newssma solar aktie news sma\
\ solar aktie newsdelivery hero aktie news delivery hero aktie newsalibaba aktie\
\ news alibaba aktie newstelekom aktie news telekom aktie newsbat aktie news bat\
\ aktie newsbmw aktie news bmw aktie newszalando aktie news zalando aktie newssuper\
\ micro computer aktie news super micro computer aktie newspbb aktie news pbb\
\ aktie newsverbio aktie news verbio aktie newsm aktie news m aktie newsvw aktie\
\ news vw aktie news\n\nunternehmen\n\nkontakt\n\nservice\n\nhilfe\n\ninformationen\n\
\nimpressum tracking\n\nfolgen sie uns auf\n\n finanzennet bei instagram finanzennet\
\ bei facebook finanzennet bei youtube finanzennet bei twitter finanzennet bei\
\ linkedin finanzennet bei xing finanzennet rss feed\n\napps\n\nfinanzennet app\
\ app\n\nios android\n\n finanzennet ios app finanzennet android app\n\nwerbung\n\
\nfür die aufgeführten inhalte kann keine gewährleistung für die vollständigkeit\
\ richtigkeit und genauigkeit übernommen werden kursinformationen von six financial\
\ information verzögerung deutsche börse min nasdaq nyse min © finanzennet\
\ gmbh"
- text: "johnson johnson shares positive results for tar in highrisk bladder cancer\
\ pmlive\n\n \
\ \n\n \n\n \n\n \n\n \n\n advertise\n subscribe\n contact\n\
\ publications\n pme\n pme supplements\n communique\n \
\ t\n\n advertise\n subscribe\n contact\n publications\n pme\n\
\ pme supplements\n communique\n t\n\n follow follow on facebook\n\
\ follow follow on x\n follow follow on linkedin\n follow follow on rss\n\
\n pharmafile logo\n\n t cover\n\n diversity equity and inclusion\n\n communiqué\
\ cover \n\n pmlive\n\n t cover\n\n diversity equity and inclusion\n\n \
\ communiqué cover \n\n pmlive\n\n t cover\n\n diversity equity and inclusion\n\
\n communiqué cover \n\n pmlive\n\n \n news\n research\n sales\n\
\ regulatory\n healthcare\n marketing\n intelligence\n \
\ intelligence\n webinars\n podcasts\n digital handbook\n\
\ orphan drugs rare diseases\n glossary\n healthcare advertising\
\ gallery\n thought leadership\n appointments\n awards\n blogs\n \
\ digital intelligence\n smart thinking\n darwin’s medicine\n webinars\n\
\ t\n top overall\n smaller agencies\n independent agencies\n\
\ young agencies\n uk focused agencies\n about t\n pmhub\n\
\ company profiles\n press releases\n white papers and resources\n\
\ videos and podcasts\n pmhub login\n add your company\n jobs\n\
\ pme\n \n search\n \n more results\n \n \
\ advanced search\n \n\njohnson johnson shares positive results for tar\
\ in highrisk bladder cancer\n\n\nmore than cases of bladder cancer are diagnosed\
\ in the us every year\n\n pmlive\n\njohnson johnson jj has shared promising\
\ results for its investigational bladder cancer treatment approach tar at this\
\ year’s american urological association annual meeting\n\nmore than people are\
\ diagnosed with bladder cancer in the us every year with nonmuscleinvasive bladder\
\ cancer nmibc accounting for up to of all newly diagnosed cases\n\nradical cystectomy\
\ the removal of the bladder and nearby structures and organs is currently recommended\
\ for nmibc patients who fail standardofcare bacillus calmetteguérin bcg immunotherapy\
\ however as nmibc usually affects older patients many may be unwilling or unfit\
\ to undergo this procedure\n\ntar is an investigational targeted releasing system\
\ which enables the controlled release of the chemotherapy drug gemcitabine into\
\ the bladder this increases the amount of time the drug delivery system spends\
\ in the bladder and sustains local drug exposure according to jj\n\ncohort two\
\ of the phase b sunrise trial has been evaluating tar as a monotherapy in patients\
\ with bcgunresponsive highrisk nmibc with carcinoma in situ who are ineligible\
\ for or decline radical cystectomy\n\nresults demonstrated a centrally confirmed\
\ complete response cr rate of with of crs achieved at the first disease assessment\
\ at week and four of five patients who have completed two years of treatment\
\ remaining in cr\n\nthe estimated oneyear duration of response rate is with\
\ median followup in responders of weeks additionally remained in cr at the\
\ data cutoff in january and none of the responders progressed to muscleinvasive\
\ bladder cancer or metastasis\n\n“the high cr rate and durability of these responses\
\ observed in patients treated with tar underscores the potential of this treatment\
\ approach for patients with bcgunresponsive highrisk nmibc” said presenting author\
\ joseph jacob department of urology at upstate medical university\n\nsunrise\
\ is also evaluating tar which has already been granted breakthrough therapy designation\
\ by the us food and drug administration in combination with the investigational\
\ antipd monoclonal antibody cetrelimab or cetrelimab alone in the same patient\
\ population\n\nchristopher cutie vice president disease area leader bladder cancer\
\ jj innovative medicine said “these results reinforce the potential of tar to\
\ transform the treatment landscape and our ongoing dedication to address unmet\
\ needs for patients facing this challenging disease”\n\narticle by emily kimber\n\
\nth may \n\nfrom research\n\njohnson johnson nonmuscleinvasive bladder cancer\
\ oncology sunrise tar\n\n \n\n \n\nsubscribe to our email news alerts\n\n\
\ latest jobs from pharmarole\n\naccount specialist respiratory kent medway\
\ account specialist respiratory kent medway\n\nterritory sales manager ostomy\
\ care wales south mids territory sales manager ostomy care wales south mids\n\
\nkey account manager urology east anglia beds bucks key account manager urology\
\ east anglia beds bucks\n\nterritory sales manager north london east anglia\
\ territory sales manager north london east anglia\n\nintegrated care specialist\
\ north west yorkshire integrated care specialist north west yorkshire\n\n\
territory sales manager ostomy care wales south mids territory sales manager\
\ ostomy care wales south mids\n\n \n\n \n\n \n\n latest content\n\n novo\
\ nordisk’s semaglutide approved by mhra to prevent cardiovascular event risk\n\
\ nhs figures reveal record number of people in england being diagnosed with\
\ dementia\n merck’s investigational rsv monoclonal antibody clesrovimab shown\
\ to protect infants\n gsk’s viiv shares positive headtohead results for twodrug\
\ hiv regimen dovato\n researchers develop ai model to identify breast cancer\
\ stages and progression\n\n latest intelligence\n\n the omnichannel wonderland\
\ of opportunities\n women in pharma\n dementia – risk factors research and\
\ treatment\n collaborating for change in rheumatology\n pharma’s content\
\ conundrum\n\n quick links\n\n digital handbook\n the gallery\n healthcare\
\ glossary\n how to advertise\n\n orphan drugs and rare dis\n pme supplements\n\
\ social media hub\n webinars\n\n \n\n \n\n about us\n privacy\n terms\
\ and conditions\n sitemap\n pmgroup worldwide ltd\n subscribeunsubscribe\n\
\n about us\n privacy\n terms and conditions\n sitemap\n pmgroup worldwide\
\ ltd\n subscribeunsubscribe\n\n \n\n blob\n\nto provide\
\ the best experiences we use technologies like cookies to store andor access\
\ device information consenting to these technologies will allow us to process\
\ data such as browsing behaviour or unique ids on this site not consenting or\
\ withdrawing consent may adversely affect certain features and functions privacy\
\ policy website terms and conditions\n\nessentialessentialstatisticsstatisticsmarketingmarketing\n\
\naccept cookiessave settings\n\nx\n\ncookie settings"
pipeline_tag: text-classification
inference: true
base_model: sentence-transformers/paraphrase-mpnet-base-v2
model-index:
- name: SetFit with sentence-transformers/paraphrase-mpnet-base-v2
results:
- task:
type: text-classification
name: Text Classification
dataset:
name: Unknown
type: unknown
split: test
metrics:
- type: accuracy
value: 0.43103448275862066
name: Accuracy
---
# SetFit with sentence-transformers/paraphrase-mpnet-base-v2
This is a [SetFit](https://github.com/huggingface/setfit) model that can be used for Text Classification. This SetFit model uses [sentence-transformers/paraphrase-mpnet-base-v2](https://huggingface.co/sentence-transformers/paraphrase-mpnet-base-v2) as the Sentence Transformer embedding model. A [LogisticRegression](https://scikit-learn.org/stable/modules/generated/sklearn.linear_model.LogisticRegression.html) instance is used for classification.
The model has been trained using an efficient few-shot learning technique that involves:
1. Fine-tuning a [Sentence Transformer](https://www.sbert.net) with contrastive learning.
2. Training a classification head with features from the fine-tuned Sentence Transformer.
## Model Details
### Model Description
- **Model Type:** SetFit
- **Sentence Transformer body:** [sentence-transformers/paraphrase-mpnet-base-v2](https://huggingface.co/sentence-transformers/paraphrase-mpnet-base-v2)
- **Classification head:** a [LogisticRegression](https://scikit-learn.org/stable/modules/generated/sklearn.linear_model.LogisticRegression.html) instance
- **Maximum Sequence Length:** 512 tokens
- **Number of Classes:** 2 classes
### Model Sources
- **Repository:** [SetFit on GitHub](https://github.com/huggingface/setfit)
- **Paper:** [Efficient Few-Shot Learning Without Prompts](https://arxiv.org/abs/2209.11055)
- **Blogpost:** [SetFit: Efficient Few-Shot Learning Without Prompts](https://huggingface.co/blog/setfit)
### Model Labels
| Label | Examples |
|:------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | - 'paradigmshifting new therapies are helping people with the disease lead longer more comfortable lives for bladder cancer awareness month learn how johnson johnson is helping to change the treatment landscape\n\nsome of the early signs of bladder cancer can be easy to dismiss lower back pain painful or frequent urination these can point to any number of benign conditions including urinary tract infection and kidney stones it’s the unsettling discovery of blood in the urine that sends most people with bladder cancer in search of medical advice\n\nbladder cancer is the ninth most common cancer worldwide about one in four cases is considered muscleinvasive bladder cancer mibc meaning the tumor has penetrated the bladder’s muscular wall or has spread outside the organ mibc is aggressive and typically requires radiation or complete removal of the bladder a procedure called a cystectomy at the time of first diagnosis most bladder cancers are nonmuscleinvasive they arise in the bladder lining and tend to respond well to a combination of surgery immunotherapy and chemotherapy\n\nimmunotherapy and chemotherapy are frequently delivered directly into the bladder although those treatments remain a mainstay of bladder cancer care today their effectiveness is limited a patient can hold these drugs in their bladder for only so long “after a few hours the patient voids the medication” explains chris cutie md vice president disease area leader bladder cancer johnson johnson innovative medicine\n\nresearchers at johnson johnson have come up with a novel investigational option to help address this problem a targeted releasing system that is placed in the bladder and stays there for weeks at a time continuously exposing urine and bladder tissue to therapy it’s just one of the new approaches the company is working on to improve the lives and longevity of patients with bladder cancer we spoke to dr cutie as well as sumeet bhanvadia md senior director johnson johnson innovative medicine to learn more about this disease and the new treatments that are changing the way patients fight it\n\n\nsmoking—as well as onthejob exposures—can raise your risk\nsmoking is the single biggest risk factor associated with bladder cancer in fact half of all bladder cancer cases can be linked to cigarette use it’s easy to see why after tobacco’s cancercausing substances carcinogens get absorbed into the bloodstream they’re filtered by the kidneys and then collect in the urine exposing the bladder to high levels of toxic chemicals which can damage the dna in the cells lining the bladder\n\nbladder cancer may actually be driven in some part and in some forms by androgen receptors\nchris cutie md\nvice president disease area leader bladder cancer johnson johnson innovative medicine\nbut cigarettes aren’t the only culprit exposure to other types of chemicals can also raise a person’s risk “people who work with hair dye in salons tend to have higher rates of bladder cancer” says dr cutie and those who work with the kinds of toxic dyes paints and solvents often used in heavy industry—like steelmaking—also face a higher chance of developing the disease\n\nmen carry a higher risk for developing bladder cancer than women and are three times more likely to get it used to be experts thought that was because more men smoke and work in industrial jobs but that thinking is changing dr cutie says research suggests that the gender disparity in bladder cancer rates may be partly attributable to hormones “it looks like bladder cancer may actually be driven in some part and in some forms by androgen receptors” dr cutie says referring to proteins on the surface of cells that bind to male hormones such as testosterone\n\nandrogen hormones and androgen receptors play a role in immune function to fight cancer—or any other disease or invader—healthy immune function is critical “when i was in medical school we were trained to look at the bladder as this simple storage organ and nothing more” dr cutie says “but that view has shifted we now know it’s also an immunogenic organ that plays an important role in immune recognition and immune signaling” researchers are still learning about the androgen receptor’s role in bladder cancer\n\n\nas with most cancers early diagnosis improves patient outcomes\ncurrently there is no recommended screening for bladder cancer but researchers are exploring whether it makes sense to screen highrisk groups like smokers and former smokers\n\ntransitional cell carcinoma micrographbladder cancer section\nmost bladder cancers are urothelial in origin also called transitionalcell because the cells change shape and arise on the surface of the cells that line the urinefacing side of the bladder among those most are nonmuscle invasive slowgrowing and highly treatable once the cancer enters the bladder muscle or spreads to lymph nodes or beyond however it becomes harder to treat dr cutie says\n\nchemotherapy can be effective but because many patients are older and have other health problems it isn’t always tolerable a cystectomy also requires creation of a urinary diversion made of intestine overall it’s a complex operation that carries significant risks for elderly people and one that has a significant impact on quality of life according to dr bhanvadia about of patients who have their bladder removed will suffer complications within the first few months of surgery “overall half of people with muscleinvasive bladder cancer will develop metastases within years even if they have received comprehensive treatments” she adds “whether cancerous cells are found in the lymph nodes at the time of surgery has the biggest impact on survival outcomes which is why early diagnosis has a huge impact on patient outcomes”\n\n\nyou can live with bladder cancer\ncaught early bladder cancer can be managed but it’s prone to recurring—which puts patients on the hook for followups for the rest of their lives “bladder cancer is currently incurable so patients have to be followed forever” says dr cutie “that means sending in periodic urine tests and having your bladder inspected every three months with a cystoscope or camera which is burdensome costly and uncomfortable”\n\nnot surprisingly a significant percentage of patients with bladder cancer suffer from mental health issues such as anxiety and depression “when you check these patients and say to them ‘hey i didn’t see anything on exam today’ they smile and give you a high five—and then they realize they need a followup appointment in three months” dr cutie says “you can see their faces fall”\n\n\nafter a long pause research is advancing fast\nin the mid s researchers made a big discovery bladder cancer appeared to respond to immunotherapy bcg short for bacille calmetteguerin a vaccine originally developed in the early s for tuberculosis could be altered in a way that helped the body’s immune system recognize and kill bladder cancer cells in bcg became the first immunotherapy for cancer approved by the fda for more than years it’s been the standard of care\n\nand yet following that historymaking advancement progress in the treatment of bladder cancer slowed to a crawl “for decades bladder cancer research was a wasteland” dr cutie says “there was very little innovation”\n\ntaking the chemotherapy agent and putting it into this innovative system that allows for continuous and lowdose delivery may improve effectiveness while at the same time minimizing side effects to the patient\nsumeet bhanvadia md\nsenior director johnson johnson innovative medicine\neven today latestage bladder cancer requires radical treatment with the removal of the bladder patients who undergo cystectomy must adapt to life after surgery with a urinary stoma a bag that collects urine outside of the body\n\ntreatments for earlierstage bladder cancer have been slow to evolve too bcg and chemotherapy have been used for decades traditionally patients received these therapies by having them injected through a tube placed into the bladder through the urethra a major limitation of this approach is that while these medications do have the capacity to kill these bladder cancer cells the medication is only in contact with malignant cells for a few hours limiting the effectiveness\n\ndr cutie and his colleagues knew there had to be a different way to deliver potent bladder cancer therapies based on results from ongoing clinical studies a version of the aforementioned targeted delivery system which allows low doses of chemotherapy to be released in the bladder slowly over weeks received breakthrough therapy designation from the fda for potential future use in patients with bcgunresponsive highrisk nonmuscleinvasive bladder cancer who are ineligible for or don’t want cystectomy\n\n“taking the chemotherapy agent that we know is effective against bladder cancer cells and putting it into this innovative system that allows for continuous and lowdose delivery may improve effectiveness while at the same time minimizing side effects to the patient” dr bhanvadia says “this could make a meaningful difference for patients”\n\n\ntreatments have come a long way—and they’re improving\nan approved systemic treatment for patients with advanced or metastatic urothelial cancer whose tumor has a specific abnormal gene works by blocking the activity of the gene in cancer cells and in healthy cells throughout the body “but treatments are only effective if they work and are also well tolerated” says dr bhanvadia as such researchers and physicianscientists at johnson johnson are also studying ways to administer this targeted medicine that may reduce side effects without compromising effectiveness this includes a targeted releasing system that delivers the drug directly into the bladder again with sustained slow delivery\n\nno two cancer patients have the same genetic profile and tailoring their treatment to their unique characteristics may improve their outcomes as the emerging field of precision medicine grows and as additional genespecific therapies become available patients will have more options that’s a huge win for patients says dr cutie'
- 'approval is based on results from the phase papillon study which demonstrated rybrevant® plus chemotherapy reduced the risk of disease progression or death by percent versus chemotherapy alone in patients with previously untreated nsclc with egfr exon insertion mutations\n\nnational comprehensive cancer network ® nccn ® updated its nccn clinical practice guidelines in oncology nccn guidelines ® to recommend amivantamabvmjw rybrevant® plus chemotherapy as a preferred firstline regimen for patients with nsclc with egfr exon insertion mutations\n\nraritan new jersey march – johnson johnson nyse jnj announced today that following a priority review the us food and drug administration fda has approved rybrevant® amivantamabvmjw in combination with chemotherapy carboplatinpemetrexed for the firstline treatment of patients with locally advanced or metastatic nonsmall cell lung cancer nsclc with epidermal growth factor receptor egfr exon insertion mutations as detected by an fdaapproved test this fda action converts the may accelerated approval of rybrevant® to a full approval based on the confirmatory phase papillon study\n\n“when aiming for the best possible treatment outcomes a targeted approach should be used in the first line for patients with egfr exon insertion mutations as this is a commonly applied practice for patients with nsclc harboring other molecular driver alterations” said joshua k sabari md an oncologist at nyu langone’s perlmutter cancer center and study investigator “the results observed in the papillon study showed significant improvement in progressionfree survival supporting the use of this regimen as the potential standardofcare in the firstline treatment of these patients”\n\nworldwide lung cancer is one of the most common cancers with nsclc making up to percent of all lung cancer cases alterations in egfr are the most common actionable driver mutations in nsclc clinical data show patients with egfr exon insertion mutations generally experience limited benefits with currently approved thirdgeneration egfr tyrosine kinase inhibitors and chemotherapy nsclc driven by egfr exon insertion mutations carries a worse prognosis and shorter survival rates compared with lung cancer driven by other egfr driver mutations\n\n“for patients with lung cancer and their families each breakthrough in treatment provides not only a new option but a potential lifeline the approval of rybrevant plus chemotherapy heralds a promising new firstline treatment option for patients newly diagnosed with nonsmall cell lung cancer where their driver mutation is an egfr exon insertion” said marcia horn executive director of the exon group and ceo of ican international cancer advocacy network “this new regimen is a major advance over chemotherapy alone we’ve seen firsthand the extended survival that exon group patients experienced on rybrevant plus chemotherapy in the papillon study and we’re delighted that this historic treatment option which specifically targets the egfr exon insertion mutation has been approved”\n\nthe fda approval is based on positive results from the randomized openlabel phase papillon study which showed rybrevant® plus chemotherapy resulted in a percent reduction in the risk of disease progression or death compared to chemotherapy alone results also showed treatment with rybrevant® plus chemotherapy improved objective response rate orr and progressionfree survival pfs based on papillon data the national comprehensive cancer network ® nccn ® updated its’ nccn clinical practice guidelines nccn guidelines® to include a category recommendation for amivantamabvmjw rybrevant® plus chemotherapy as a preferred firstline therapy for patients with nsclc with egfr exon insertion mutations †‡\n\n“we are redefining care for patients with nonsmall cell lung cancer by advancing innovative regimens that can be used early with the goal of extending survival” said kiran patel md vice president clinical development solid tumors johnson johnson innovative medicine “rybrevant plus chemotherapy is the first targeted approach approved for the firstline treatment of patients with nsclc with egfr exon insertion mutations we look forward to building on this latest milestone as we continue to accelerate our transformative lung cancer portfolio”\n\nwarnings and precautions include infusion related reactions irr interstitial lung disease ildpneumonitis dermatologic adverse reactions ocular toxicity and embryofetal toxicity the most common adverse reactions percent were rash nail toxicity stomatitis irr fatigue edema constipation decreased appetite nausea covid diarrhea and vomiting the most common grade or laboratory abnormalities percent were decreased albumin increased alanine aminotransferase increased gammaglutamyl transferase decreased sodium decreased potassium decreased magnesium and decreases in white blood cells hemoglobin neutrophils platelets and lymphocytes\n\nabout the papillon study\npapillon nct is a randomized openlabel phase study evaluating the efficacy and safety of rybrevant® in combination with chemotherapy compared with chemotherapy alone in newly diagnosed patients with advanced or metastatic nsclc characterized by egfr exon insertion mutations the primary endpoint of the study is pfs using recist v guidelines§ as assessed by blinded independent central review bicr secondary endpoints include orr pfs after first subsequent therapy time to symptomatic progression and overall survival os patients who received chemotherapy alone were allowed to receive rybrevant® monotherapy in the secondline setting after confirmation of disease progression\n\nabout rybrevant®\nrybrevant® amivantamabvmjw a fullyhuman bispecific antibody targeting egfr and met with immune celldirecting activity is approved in the us europe and in other markets around the world as monotherapy for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon insertion mutations as detected by an fdaapproved test whose disease has progressed on or after platinumbased chemotherapy this indication is approved under accelerated approval based on orr and duration of response dor continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials rybrevant® is also approved in the us in combination with chemotherapy carboplatin and pemetrexed for the firstline treatment of adult patients with locally advanced or metastatic nsclc with egfr exon insertion mutations as detected by an fdaapproved test in october a type ii extension of indication application was submitted to the european medicines agency ema seeking approval of rybrevant® for this indication in december johnson johnson submitted an sbla together with a new drug application nda to the us fda for rybrevant® in combination with lazertinib for the firstline treatment of adult patients with locally advanced or metastatic nsclc with egfr exon deletions or lr substitution mutations as detected by an fdaapproved test this submission is based on the phase mariposa study and was granted priority review in february a marketing authorization application maa and type ii extension of indication application were also submitted to the ema seeking approval of lazertinib in combination with rybrevant® based on the mariposa study in november johnson johnson submitted an sbla to the us fda for rybrevant® in combination with chemotherapy for the treatment of patients with egfrmutated nsclc who progressed on or after osimertinib based on the mariposa study a type ii extension of indication application was also submitted to the ema seeking the approval of rybrevant® for this indication\n\nthe nccn clinical practice guidelines in oncology nccn guidelines® for nsclc prefer nextgeneration sequencingbased strategies over polymerase chain reactionbased approaches for the detection of egfr exon insertion variants the nccn guidelines® include\n\namivantamabvmjw rybrevant® plus carboplatin and pemetrexed as a preferred category recommendation firstline therapy in treatmentnaive patients with newly diagnosed advanced or metastatic egfr exon insertion mutationpositive advanced nsclc or as a subsequent therapy option category a recommendation for patients that have progressed on or after platinumbased chemotherapy with or without immunotherapy and have egfr exon insertion mutationpositive advanced nsclc †‡\namivantamabvmjw rybrevant® plus chemotherapy as a preferred category recommendation subsequent therapy for patients with locally advanced or metastatic ncslc with egfr exon deletions or exon lr mutations who experienced disease progression after treatment with osimertinib †‡\namivantamabvmjw rybrevant® as a subsequent therapy option category a recommendation for patients that have progressed on or after platinumbased chemotherapy with or without an immunotherapy and have egfr exon insertion mutationpositive nsclc †‡\nin addition to the phase papillon study rybrevant® is being studied in multiple clinical trials in nsclc including\n\nthe phase mariposa nct study evaluating the efficacy and safety of rybrevant® and chemotherapy in patients with locally advanced or metastatic egfr exdel or lr substitution nsclc who had disease progression on or after treatment with osimertinib data for this randomized phase study presented at the esmo congress demonstrated statistically significant and clinically meaningful improvement in pfs in patients receiving rybrevant® plus chemotherapy with and without lazertinib versus chemotherapy\nthe phase mariposa nct study assessing rybrevant® in combination with lazertinib a novel thirdgeneration egfr tki versus osimertinib and versus lazertinib alone in the firstline treatment of patients with locally advanced or metastatic nsclc with egfr exon deletions exdel or lr substitution mutations data for this randomized phase study presented at the esmo congress showed statistically significant and clinically meaningful improvement in progressionfree survival in patients with egfrmutated advanced nsclc treated with rybrevant® plus lazertinib versus osimertinib\nthe phase chrysalis nct study evaluating rybrevant® in participants with advanced nsclc\nthe phase b chrysalis nct study evaluating rybrevant® in combination with lazertinib and lazertinib as a monotherapy in patients with advanced nsclc with egfr mutations\nthe phase paloma nct study assessing the feasibility of subcutaneous sc administration of amivantamab based on safety and pharmacokinetics and to determine a dose dose regimen and formulation for amivantamab sc delivery\nthe phase paloma nct study assessing subcutaneous amivantamab in participants with advanced or metastatic solid tumors including egfrmutated nsclc\nthe phase paloma nct study assessing lazertinib with subcutaneous amivantamab compared to intravenous amivantamab in participants with egfrmutated advanced or metastatic nsclc\nthe phase metalmark nct study assessing rybrevant® and capmatinib combination therapy in locally advanced or metastatic nsclc\nthe phase polydamas nct study assessing rybrevant® and cetrelimab combination therapy in locally advanced or metastatic nsclc\nthe phase skippirr study nct exploring how to decrease the incidence andor severity of firstdose infusionrelated reactions with rybrevant® in combination with lazertinib in relapsed or refractory egfrmutated advanced or metastatic nsclc\nthe phase cocoon study nct will evaluate enhanced dermatological care to reduce rash and paronychia in patients with egfrmutated nsclc treated firstline with amivantamab plus lazertinib\nfor more information visit \n\nabout nonsmall cell lung cancer\nworldwide lung cancer is one of the most common cancers with nsclc making up to percent of all lung cancer cases the main subtypes of nsclc are adenocarcinoma squamous cell carcinoma and large cell carcinoma among the most common driver mutations in nsclc are alterations in egfr which is a receptor tyrosine kinase controlling cell growth and division egfr mutations are present in to percent of western patients with nsclc with adenocarcinoma histology and occur in to percent of asian patients egfr exdel or egfr lr mutations are the most common egfr mutations the fiveyear survival rate for all people with advanced nsclc and egfr mutations treated with egfr tkis is less than percent patients with egfr exdel or lr mutations have a realworld fiveyear os of percent\n\nrybrevant® important safety information\n\nwarnings and precautions\nthe safety population of rybrevant® with carboplatin and pemetrexed described in warnings and precautions was based on patients in the papillon study\n\nthe safety population of rybrevant® as a single agent described in warnings and precautions was based on patients in the chrysalis study\n\ninfusionrelated reactions\nrybrevant® can cause infusionrelated reactions irr signs and symptoms of irr include dyspnea flushing fever chills nausea chest discomfort hypotension and vomiting\n\nrybrevant® with carboplatin and pemetrexed\n\nrybrevant in combination with carboplatin and pemetrexed can cause infusionrelated reactions based on the safety population infusionrelated reactions occurred in of patients treated with rybrevant® in combination with carboplatin and pemetrexed including grade adverse reactions the incidence of infusion modifications due to irr was and of patients permanently discontinued rybrevant\n\nrybrevant®as a single agent\n\nbased on the safety population irr occurred in of patients treated with rybrevant® among patients receiving treatment on week day experienced an irr while the incidence of irr was with the day infusion with the week infusion and cumulatively with subsequent infusions of the reported irrs were grade were grade and were grade the median time to onset was hour range to hours after start of infusion the incidence of infusion modifications due to irr was and of patients permanently discontinued rybrevant® due to irr\n\npremedicate with antihistamines antipyretics and glucocorticoids and infuse rybrevant® as recommended administer rybrevant® via a peripheral line on week and week monitor patients for any signs and symptoms of infusion reactions during rybrevant® infusion in a setting where cardiopulmonary resuscitation medication and equipment are available interrupt infusion if irr is suspected reduce the infusion rate or permanently discontinue rybrevant® based on severity\n\ninterstitial lung diseasepneumonitis\nrybrevant® can cause interstitial lung disease ildpneumonitis\n\nrybrevant® with carboplatin and pemetrexed\n\nbased on the safety population grade ildpneumonitis occurred in of patients treated with rybrevant® in combination with carboplatin and pemetrexed all patients required permanent discontinuation\n\nrybrevant® as a single agent\n\nbased on the safety population ildpneumonitis occurred in of patients treated with rybrevant® with of patients experiencing grade ildpneumonitis three patients discontinued rybrevant® due to ildpneumonitis\n\nmonitor patients for new or worsening symptoms indicative of ildpneumonitis eg dyspnea cough fever immediately withhold rybrevant® in patients with suspected ildpneumonitis and permanently discontinue if ildpneumonitis is confirmed\n\ndermatologic adverse reactions\nrybrevant® can cause rash including dermatitis acneiform pruritus and dry skin\n\nrybrevant®with carboplatin and pemetrexed\n\nrybrevant in combination with carboplatin and pemetrexed can cause dermatologic adverse reactions based on the safety population rash occurred in of patients treated with rybrevant® in combination with carboplatin and pemetrexed including grade adverse reactions rash leading to dose reductions occurred in of patients permanently discontinued rybrevant® and discontinued pemetrexed\n\nrybrevant® as a single agent\n\nbased on the safety population rash occurred in of patients treated with rybrevant® including grade rash in of patients the median time to onset of rash was days range to days rash leading to dose reduction occurred in of patients and rybrevant® was permanently discontinued due to rash in of patients\n\ntoxic epidermal necrolysis occurred in one patient treated with rybrevant® as a single agent\n\ninstruct patients to limit sun exposure during and for months after treatment with rybrevant® advise patients to wear protective clothing and use broadspectrum uvauvb sunscreen alcoholfree emollient cream is recommended for dry skin\n\nif skin reactions develop start topical corticosteroids and topical andor oral antibiotics for grade reactions add oral steroids and consider dermatologic consultation promptly refer patients presenting with severe rash atypical appearance or distribution or lack of improvement within weeks to a dermatologist withhold dose reduce or permanently discontinue rybrevant® based on severity\n\nocular toxicity\nrybrevant® can cause ocular toxicity including keratitis dry eye symptoms conjunctival redness blurred vision visual impairment ocular itching and uveitis\n\nrybrevant® with carboplatin and pemetrexed\n\nbased on the safety population rybrevant® in combination with carboplatin and pemetrexed can cause ocular toxicity including blepharitis dry eye conjunctival redness blurred vision and eye pruritus all events were grade \n\nrybrevant® as a single agent\n\nbased on the safety population keratitis occurred in and uveitis occurred in of patients treated with rybrevant® all events were grade promptly refer patients presenting with eye symptoms to an ophthalmologist withhold dose reduce or permanently discontinue rybrevant® based on severity\n\nembryofetal toxicity\nbased on its mechanism of action and findings from animal models rybrevant® can cause fetal harm when administered to a pregnant woman advise females of reproductive potential of the potential risk to the fetus advise female patients of reproductive potential to use effective contraception during treatment and for months after the last dose of rybrevant®\n\nadverse reactions\nrybrevant® with carboplatin and pemetrexed\n\nfor the patients in the papillon clinical trial who received rybrevant® in combination with carboplatin and pemetrexed the most common adverse reactions were rash nail toxicity stomatitis infusionrelated reaction fatigue edema constipation decreased appetite nausea covid diarrhea and vomiting the most common grade to laboratory abnormalities were decreased albumin increased alanine aminotransferase increased gammaglutamyl transferase decreased sodium decreased potassium decreased magnesium and decreases in white blood cells hemoglobin neutrophils platelets and lymphocytes \n\nserious adverse reactions occurred in of patients who received rybrevant® in combination with carboplatin and pemetrexed serious adverse reactions in of patients included rash pneumonia ild pulmonary embolism vomiting and covid fatal adverse reactions occurred in patients due to pneumonia cerebrovascular accident cardiorespiratory arrest covid sepsis and death not otherwise specified\n\nrybrevant® as a single agent\n\nfor the patients in the chrysalis clinical trial who received rybrevant® as a single agent the most common adverse reactions were rash irr paronychia musculoskeletal pain dyspnea nausea fatigue edema stomatitis cough constipation and vomiting the most common grade to laboratory abnormalities were decreased lymphocytes decreased albumin decreased phosphate decreased potassium increased alkaline phosphatase increased glucose increased gammaglutamyl transferase and decreased sodium \n\nserious adverse reactions occurred in of patients who received rybrevant® serious adverse reactions in of patients included pulmonary embolism pneumonitisild dyspnea musculoskeletal pain pneumonia and muscular weakness fatal adverse reactions occurred in patients due to pneumonia and patient due to sudden death\n\nplease read the full prescribing information for rybrevant®\n\nabout johnson johnson\nat johnson johnson we believe health is everything our strength in healthcare innovation empowers us to build a world where complex diseases are prevented treated and cured where treatments are smarter and less invasive and solutions are personal through our expertise in innovative medicine and medtech we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity learn more at or at follow us at janssenus and jnjinnovmed janssen research development llc and janssen biotech inc are both johnson johnson companies\n\ncautions concerning forwardlooking statements\nthis press release contains “forwardlooking statements” as defined in the private securities litigation reform act of regarding product development and the potential benefits and treatment impact of rybrevant® amivantamabvmjw and lazertinib the reader is cautioned not to rely on these forwardlooking statements these statements are based on current expectations of future events if underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize actual results could vary materially from the expectations and projections of janssen research development llc janssen biotech inc and johnson johnson risks and uncertainties include but are not limited to challenges and uncertainties inherent in product research and development including the uncertainty of clinical success and of obtaining regulatory approvals uncertainty of commercial success competition including technological advances new products and patents attained by competitors challenges to patents changes in behavior and spending patterns of purchasers of health care products and services changes to applicable laws and regulations including global health care reforms and trends toward health care cost containment a further list and descriptions of these risks uncertainties and other factors can be found in johnson johnson’s annual report on form k for the fiscal year ended january including in the sections captioned “cautionary note regarding forwardlooking statements” and “item a risk factors” and in johnson johnson’s subsequent quarterly reports on form q and other filings with the securities and exchange commission copies of these filings are available online at or on request from johnson johnson none of janssen research development llc janssen biotech inc and johnson johnson undertakes to update any forwardlooking statement as a result of new information or future events or developments'
- 'submissions supported by data from landmark phase mariposa study which showed statistically significant and clinically meaningful improvement in progressionfree survival in patients with egfrmutated advanced nsclc treated with rybrevant® plus lazertinib versus osimertinib\n\nraritan nj dec prnewswire johnson johnson announced today the submission of a supplemental biologics license application sbla to the us food and drug administration fda together with a new drug application nda seeking the approval of rybrevant® amivantamabvmjw in combination with lazertinib for the firstline treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer nsclc with epidermal growth factor receptor egfr exon deletions or lr substitution mutations as detected by an fdaapproved test based on the phase mariposa study this marks the third submission from the rybrevant® clinical development program in four months following sbla submissions for mariposa and papillon\n\nthe combination of rybrevant® and lazertinib demonstrated statistically significant and clinically meaningful improvement in progressionfree survival compared to osimertinib in patients with previously untreated egfrmutated nsclc this remains an area of high unmet need as patients often experience treatment resistance and disease progression on currently available therapies said kiran patel md vice president clinical development solid tumors johnson johnson innovative medicine we believe this targeted chemotherapyfree regimen may have the potential to transform the treatment of egfrmutated nsclc and we look forward to working with the fda in review of these applications \n\nthese applications are supported by data from the phase mariposa nct study evaluating the efficacy and safety of rybrevant® in combination with lazertinib versus osimertinib and versus lazertinib alone in firstline treatment of patients with locally advanced or metastatic nsclc with egfr exdel or lr substitution mutations results from the mariposa study were recently presented in a presidential symposium at the european society of medical oncology esmo congress abstract lba\n\nabout the mariposa study\n\nmariposa nct which enrolled patients is a randomized phase study evaluating rybrevant® amivantamabvmjw a bispecific antibody targeting egfr and mesenchymalepithelial transition met in combination with lazertinib an oral thirdgeneration epidermal growth factor receptor egfr tyrosine kinase inhibitor tki versus osimertinib and versus lazertinib alone in firstline treatment of patients with locally advanced or metastatic nsclc with egfr exdel or lr substitution mutations the primary endpoint of the study is progressionfree survival pfs using recist v guidelines as assessed by blinded independent central review bicr secondary endpoints include os orr dor second progressionfree survival pfs and intracranial pfs\n\nthe mariposa study required all patients to have serial brain imaging with mris in order to detect or monitor brain metastases a measure not implemented in most prior studies for egfrmutated nsclc the primary endpoint of pfs in mariposa included these central nervous system cns events detected by serial brain mris extracranial pfs which may more closely approximate what would be seen in other trials was also explored in mariposa \n\nabout rybrevant® \n\nrybrevant® amivantamabvmjw a fullyhuman bispecific antibody targeting egfr and met with immune celldirecting activity received accelerated approval by the us food and drug administration fda in may for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon insertion mutations as detected by an fdaapproved test whose disease has progressed on or after platinumbased chemotherapy this indication is approved under accelerated approval based on orr and dor continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials rybrevant® has also received approval from health authorities in europe as well as other markets around the world the supplemental biologics license application sbla johnson johnson submitted to the us fda for rybrevant® in combination with chemotherapy carboplatinpemetrexed for the firstline treatment of patients with nsclc with egfr exon insertion mutations has been granted priority review in october a type ii extension of indication application was submitted to the european medicines agency ema seeking approval of rybrevant® for this indication in november johnson johnson submitted an sbla to the us fda for rybrevant® in combination with chemotherapy for the treatment of patients with egfrmutated nsclc who progressed on or after osimertinib a type ii extension of indication application was also submitted to the ema seeking the approval of rybrevant® for this indication\n\nthe nccn clinical practice guidelines in oncology nccn guidelines® for nsclc‡ prefer nextgeneration sequencing–based strategies over polymerase chain reaction–based approaches for the detection of egfr exon insertion variants and include amivantamabvmjw rybrevant® as a subsequent therapy option with a category a recommendation for patients that have progressed on or after platinumbased chemotherapy with or without immunotherapy and have egfr exon insertion mutationpositive advanced nsclc§\n\nin addition to the phase mariposa study rybrevant® is being studied in multiple clinical trials in nsclc including\n\nthe phase mariposa nct study evaluating the efficacy and safety of rybrevant® and chemotherapy in patients with locally advanced or metastatic egfr exdel or lr substitution nsclc who had disease progression on or after treatment with osimertinib data for this randomized phase study presented at the esmo congress demonstrated statistically significant and clinically meaningful improvement in pfs in patients receiving rybrevant® plus chemotherapy with and without lazertinib versus chemotherapy\nthe phase papillon nct study assessing rybrevant® in combination with carboplatinpemetrexed versus carboplatinpemetrexed in the firstline treatment of patients with advanced or metastatic nsclc with egfr exon insertion mutations data for this randomized phase study presented at the esmo congress demonstrated statistically significant and clinically meaningful improvement in pfs in patients receiving rybrevant® versus chemotherapy\nthe phase chrysalis nct study evaluating rybrevant® in participants with advanced nsclc\nthe phase b chrysalis nct study evaluating rybrevant® in combination with lazertinib and lazertinib as a monotherapy in patients with advanced nsclc with egfr mutations\nthe phase paloma nct study assessing the feasibility of subcutaneous sc administration of amivantamab based on safety and pharmacokinetics and to determine a dose dose regimen and formulation for amivantamab sc delivery\nthe phase paloma nct study assessing subcutaneous amivantamab in participants with advanced or metastatic solid tumors including egfrmutated nsclc\nthe phase paloma nct study assessing lazertinib with subcutaneous amivantamab compared to intravenous amivantamab in participants with egfrmutated advanced or metastatic nsclc\nthe phase metalmark nct study assessing rybrevant® and capmatinib combination therapy in locally advanced or metastatic nsclc\nthe phase polydamas nct study assessing rybrevant® and cetrelimab combination therapy in locally advanced or metastatic nsclc\nthe phase skippirr study nct exploring how to decrease the incidence andor severity of firstdose infusionrelated reactions with rybrevant® in combination with lazertinib in relapsed or refractory egfrmutated advanced or metastatic nsclc\nthe phase cocoon study nct will evaluate enhanced dermatological care to reduce rash and paronychia in patients with egfrmutated nsclc treated firstline with amivantamab plus lazertinib\nfor more information visit \n\nabout lazertinib\n\nin janssen biotech inc entered into a license and collaboration agreement with yuhan corporation for the development of lazertinib lazertinib is an oral thirdgeneration brainpenetrant egfr tki that targets both the tm mutation and activating egfr mutations while sparing wildtype egfr an analysis of the efficacy and safety of lazertinib from the phase laser study was published in the journal of clinical oncology in \n\nabout nonsmall cell lung cancer\n\nworldwide lung cancer is one of the most common cancers with nsclc making up to percent of all lung cancer cases the main subtypes of nsclc are adenocarcinoma squamous cell carcinoma and large cell carcinoma among the most common driver mutations in nsclc are alterations in egfr which is a receptor tyrosine kinase controlling cell growth and division egfr mutations are present in to percent of western patients with nsclc with adenocarcinoma histology and occur in to percent of asian patients egfr exdel or egfr lr mutations are the most common egfr mutations the fiveyear survival rate for all people with advanced nsclc and egfr mutations treated with egfr tkis is less than percent patients with egfr exdel or lr mutations have a realworld fiveyear os of percent\n\nrybrevant® important safety information\n\nwarnings and precautions \n\ninfusionrelated reactions \n\nrybrevant® can cause infusionrelated reactions irr signs and symptoms of irr include dyspnea flushing fever chills nausea chest discomfort hypotension and vomiting\n\nbased on the safety population irr occurred in of patients treated with rybrevant® among patients receiving treatment on week day experienced an irr while the incidence of irr was with the day infusion with the week infusion and cumulatively with subsequent infusions of the reported irrs were grade were grade and were grade the median time to onset was hour range to hours after start of infusion the incidence of infusion modifications due to irr was and of patients permanently discontinued rybrevant® due to irr\n\npremedicate with antihistamines antipyretics and glucocorticoids and infuse rybrevant® as recommended administer rybrevant® via a peripheral line on week and week monitor patients for any signs and symptoms of infusion reactions during rybrevant® infusion in a setting where cardiopulmonary resuscitation medication and equipment are available interrupt infusion if irr is suspected reduce the infusion rate or permanently discontinue rybrevant® based on severity\n\ninterstitial lung diseasepneumonitis\n\nrybrevant® can cause interstitial lung disease ildpneumonitis based on the safety population ildpneumonitis occurred in of patients treated with rybrevant® with of patients experiencing grade ildpneumonitis three patients discontinued rybrevant® due to ildpneumonitis \n\nmonitor patients for new or worsening symptoms indicative of ildpneumonitis eg dyspnea cough fever immediately withhold rybrevant® in patients with suspected ildpneumonitis and permanently discontinue if ildpneumonitis is confirmed\n\ndermatologic adverse reactions\n\nrybrevant® can cause rash including dermatitis acneiform pruritus and dry skin based on the safety population rash occurred in of patients treated with rybrevant® including grade rash in of patients the median time to onset of rash was days range to days rash leading to dose reduction occurred in of patients and rybrevant® was permanently discontinued due to rash in of patients\n\ntoxic epidermal necrolysis occurred in one patient treated with rybrevant®\n\ninstruct patients to limit sun exposure during and for months after treatment with rybrevant® advise patients to wear protective clothing and use broad spectrum uvauvb sunscreen alcoholfree emollient cream is recommended for dry skin\n\nif skin reactions develop start topical corticosteroids and topical andor oral antibiotics for grade reactions add oral steroids and consider dermatologic consultation promptly refer patients presenting with severe rash atypical appearance or distribution or lack of improvement within weeks to a dermatologist withhold dose reduce or permanently discontinue rybrevant® based on severity\n\nocular toxicity\n\nrybrevant® can cause ocular toxicity including keratitis dry eye symptoms conjunctival redness blurred vision visual impairment ocular itching and uveitis based on the safety population keratitis occurred in and uveitis occurred in of patients treated with rybrevant® all events were grade promptly refer patients presenting with eye symptoms to an ophthalmologist withhold dose reduce or permanently discontinue rybrevant® based on severity\n\nembryofetal toxicity\n\nbased on its mechanism of action and findings from animal models rybrevant® can cause fetal harm when administered to a pregnant woman advise females of reproductive potential of the potential risk to the fetus advise female patients of reproductive potential to use effective contraception during treatment and for months after the final dose of rybrevant®\n\nadverse reactions\n\nthe most common adverse reactions were rash irr paronychia musculoskeletal pain dyspnea nausea fatigue edema stomatitis cough constipation and vomiting the most common grade to laboratory abnormalities were decreased lymphocytes decreased albumin decreased phosphate decreased potassium increased alkaline phosphatase increased glucose increased gammaglutamyl transferase and decreased sodium \n\nplease read the full prescribing information for rybrevant® \n\nabout johnson johnson\n\nat johnson johnson we believe health is everything our strength in healthcare innovation empowers us to build a world where complex diseases are prevented treated and cured where treatments are smarter and less invasive and solutions are personal through our expertise in innovative medicine and medtech we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity learn more at or at follow us at janssenus and jnjinnovmed janssen research development llc and janssen biotech inc are both johnson johnson companies\n\ncautions concerning forwardlooking statements\n\nthis press release contains forwardlooking statements as defined in the private securities litigation reform act of regarding product development and the potential benefits and treatment impact of rybrevant® amivantamabvmjw and lazertinib the reader is cautioned not to rely on these forwardlooking statements these statements are based on current expectations of future events if underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize actual results could vary materially from the expectations and projections of janssen research development llc janssen biotech inc and johnson johnson risks and uncertainties include but are not limited to challenges and uncertainties inherent in product research and development including the uncertainty of clinical success and of obtaining regulatory approvals uncertainty of commercial success competition including technological advances new products and patents attained by competitors challenges to patents changes in behavior and spending patterns of purchasers of health care products and services changes to applicable laws and regulations including global health care reforms and trends toward health care cost containment a further list and descriptions of these risks uncertainties and other factors can be found in johnson johnsons annual report on form k for the fiscal year ended january including in the sections captioned cautionary note regarding forwardlooking statements and item a risk factors and in johnson johnsons subsequent quarterly reports on form q and other filings with the securities and exchange commission copies of these filings are available online at or on request from johnson johnson none of janssen research development llc janssen biotech inc and johnson johnson undertakes to update any forwardlooking statement as a result of new information or future events or developments\n\nrecist v refers to response evaluation criteria in solid tumors which is a standard way to measure how well solid tumors respond to treatment and is based on whether tumors shrink stay the same or get bigger\n\n‡the nccn content does not constitute medical advice and should not be used in place of seeking professional medical advice diagnosis or treatment by licensed practitioners nccn makes no representations or warranties and explicitly disclaims the appropriateness or applicability of the nccn content to any specific patients care or treatment\n\n§see the nccn guidelines for detailed recommendations including other treatment options\n\nthe nccn guidelines for nsclc provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories'
|
| 0 | - 'please join us for the highly anticipated eighth annual blue jacket fashion show a unique event founded by fashion designer frederick anderson benefitting zero prostate cancer sponsored by johnson johnson this exceptional gathering seamlessly blends the realms of fashion entertainment sports healthcare and media to openly address the critical issue of prostate cancer\n\nsupport for this event helps bridge the gap between racial and health disparities in prostate cancer among black men and underserved communities\n\nwith a specific emphasis on tackling racial disparities and underserved communities the blue jacket fashion show is more than just a display of style it’s a platform for meaningful conversations for a disease that impacts in men as part of this annual event there will be free screenings held in three new york city locations as well as a fashion show afterparty zero prostate cancer is proud to be the blue jackets charity partner\n\nluis a miranda jr j harrison ghee marcus samuelsson billy porter holly robinson peete don lemon nigel barker and many other celebrities who are passionate about raising awareness about prostate cancer will grace the runway this year \n\nthe blue jacket fashion show takes place on thursday february at moonlight studios in new york city you’re invited to join the fun and watch the entire blue jacket fashion show live stream right here on zeros youtube channel\n\nfeatured on the blue carpet\nthe worlds of fashion entertainment sports healthcare and media unite again for the blue jacket fashion show many have been walking the catwalk since the event launched in but there are also some exciting new faces this year \n\n\n\n\n\n\n\n\n\n\n\n\n\n\nsponsored by\njohnson johnson logo'
- 'the us house of representatives committee on china has asked the fbi and the intelligence community for a briefing on genscript biotechnology co and three subsidiaries to determine if the chinese communist party has influence over their operations\n\nin a letter dated may to the fbi and the us office of the director of national intelligence committee chair john moolenaar and ranking member raja krishnamoorthi said genscripts work with us companies and the government raises concerns about the intellectual property of us firms and could help improve chinas biotech capabilities\n\nthe three subsidiaries cited in the letter are bestzyme legend biotech and probio\n\n\ndrugmaker legend partnered with johnson johnson in to develop cancer cell therapy carvykti they sold million of the drug last year and expect sales to eventually top billion a year\n\na spokesperson for genscript said they were founded in new jersey and do not take direction from any government they added that they looked forward to speaking with the house committee\n\nlegend and jj did not immediately respond to requests for comment nor did the other subsidiaries genscript is a pharmaceutical research and manufacturing service provider with over customers in over countries and sales manufacturing and research and development presence in china the us europe and the asia pacific according to its website\n\nthe lawmakers interest in genscript comes two weeks after another committee in the house approved a bill that would restrict business with chinas wuxi apptec wuxi biologics bgi mgi and complete genomics and other possible biotech companies of concern\n\nthe bill must still get through the full house and senate before president joe biden could sign it into law but if passed it would push us pharmaceutical and healthcare companies to lessen their reliance on chinese research and manufacturing\n\ngenscripts role as a contract development and manufacturing organization including services such as the production of custom gene synthesis for companies and us government entities raises concerns about potential risks to the intellectual property of us firms and genscripts broader role in advancing the prcs china biotech capabilities the letter said \n\n© thomsonreuters all rights reserved'
- 'takeda pharmaceutical has secured an option on an alzheimer’s disease immunotherapy from ac immune that is on track to report its first phase data later this quarter exercising the option would make takeda responsible for phase testing of the therapy putting ac immune in line for up to billion in milestone payments\n\nalzheimer’s disease can be treated with antibody drugs that reduce levels of amyloid beta protein in the brain clinicalstage biotech company ac immune is developing a novel therapy that sparks the immune system to clear away amyloid plaque and takeda pharmaceutical sees enough promise in this approach to commit million for the opportunity to pick up this experimental therapy\n\nthe ac immune drug codenamed aci is currently being evaluated in the phase portion of a phase b study under the deal terms announced monday takeda’s upfront payment gives it an exclusive option to license global rights to this immunotherapy\n\naci is an immunogenic peptide that is presented to the immune system’s b cells in a way that mimics the pathological form of amyloid beta this presentation is intended to spark activity from antibodies that bind to pathological forms of the protein in preclinical research lausanne switzerlandbased ac immune has reported that the drug led to higher blood levels of immunoglobulin g antibodies that were associated with reduction in amyloid plaque in tests in monkeys ac immune reported a favorable safety profile for the drug\n\nac immune is responsible for completing the placebocontrolled phase b study which is evaluating for aci in patients with early alzheimer’s the study is also testing the immunotherapy as a treatment for patients with down syndrome under the takeda agreement the japanese pharmaceutical giant may exercise its option after it receives predefined clinical data on the first three alzheimer’s patient cohorts from the ongoing study ac immune said in a regulatory filing the first phase data on amyloid plaque reduction after six months of treatment will be reported in the current quarter potentially paving the way for phase testing ac immune said monday in its report of financial results for the first quarter of \n\n“we believe the maximum impact of aci can best be realized by partnering with takeda at this critical juncture in its development which will help us move rapidly into phase ” ac immune ceo andrea pfeifer said in a prepared statement “this agreement allows us to leverage the developmental expertise strategic vision and financial capacity of an accomplished organization that has demonstrated its ability to execute the type of comprehensive global program required for phase trials in alzheimer’s disease while allowing us to focus on completing phase b development and accelerating our efforts to replicate this success with enhanced funding for our earlystage pipeline”\n\nupdated to add the following three paragraphs with analyst commentary an antiamyloid beta or “abeta” approach already has partial validation from the fda approval of the amyloid plaque antibody busting drug leqembi from eisai as well as donanemab an eli lilly drug still under regulatory review leerink partners analyst marc goodman wrote in a march research note but safety could be a key differentiator for an alzheimer’s immunotherapy antibody drugs developed for the disease introduce the risk of amyloidrelating imaging abnormalities aria brain bleeding and swelling that is a known adverse effect of this class of therapies an earlier formulation of ac immune’s therapy yielded mixed phase data while the results showed favorable safety with no signs of aria the immune response was “suboptimal” goodman said\n\naci is a new formulation incorporating changes intended to boost the immune response goodman said translation of immune response to amyloid beta clearance andor clinical benefit remains a key question also active immunotherapy may take longer to show an effect compared with antibody drugs he added while those questions remain unanswered so far the takeda deal is positive news for ac immune goodman wrote in a monday research note\n\nonce again management has executed on a significant partnership with a big pharma company to develop an asset that has received minimal value in the stock confirming our longterm thesis that this management team can leverage its two proprietary drug discovery platforms and diversified pipeline to drive value” goodman said\n\nthe agreement makes ac immune eligible for up to billion in milestone payments which includes an option exercise fee in the lowtomidhundred millions of dollars according to the regulatory filing after exercising that option takeda will be responsible for clinical development of the alzheimer’s drug takeda will also handle regulatory submissions as well as commercialization if the drug is approved ac immune will receive royalties from takeda’s sales of the immunotherapy\n\naci would give takeda another opportunity to address alzheimer’s but with a drug candidate that has been derisked with clinical data the company previously partnered with denali therapeutics on the development of an antibody engineered to penetrate the brain to hit and activate a target called trem last august the two companies announced they would discontinue clinical development of this alzheimer’s drug after safety signals emerged in phase testing takeda also has a research collaboration with cure network dolby acceleration partners focused on developing small molecules that target tau in alzheimer’s and other brain disorders\n\nac immune has other alliances in alzheimer’s its antitau immunotherapy aci is currently in midstage clinical development under a partnership with johnson johnson subsidiary janssen pharmaceuticals a tau aggregation inhibitor is in preclinical development under a partnership with eli lilly two ac immune antibodies semorinemab and crenezumab were partnered with roche’s genentech division but after disappointing clinical trial results genentech terminated the alliance early this year returning to ac immune rights to both antibodies'
|
## Evaluation
### Metrics
| Label | Accuracy |
|:--------|:---------|
| **all** | 0.4310 |
## Uses
### Direct Use for Inference
First install the SetFit library:
```bash
pip install setfit
```
Then you can load this model and run inference.
```python
from setfit import SetFitModel
# Download from the 🤗 Hub
model = SetFitModel.from_pretrained("csong97/setfit-jnj-relevancy")
# Run inference
preds = model("johnson johnson shares positive results for tar in highrisk bladder cancer pmlive
advertise
subscribe
contact
publications
pme
pme supplements
communique
t
advertise
subscribe
contact
publications
pme
pme supplements
communique
t
follow follow on facebook
follow follow on x
follow follow on linkedin
follow follow on rss
pharmafile logo
t cover
diversity equity and inclusion
communiqué cover
pmlive
t cover
diversity equity and inclusion
communiqué cover
pmlive
t cover
diversity equity and inclusion
communiqué cover
pmlive
news
research
sales
regulatory
healthcare
marketing
intelligence
intelligence
webinars
podcasts
digital handbook
orphan drugs rare diseases
glossary
healthcare advertising gallery
thought leadership
appointments
awards
blogs
digital intelligence
smart thinking
darwin’s medicine
webinars
t
top overall
smaller agencies
independent agencies
young agencies
uk focused agencies
about t
pmhub
company profiles
press releases
white papers and resources
videos and podcasts
pmhub login
add your company
jobs
pme
search
more results
advanced search
johnson johnson shares positive results for tar in highrisk bladder cancer
more than cases of bladder cancer are diagnosed in the us every year
pmlive
johnson johnson jj has shared promising results for its investigational bladder cancer treatment approach tar at this year’s american urological association annual meeting
more than people are diagnosed with bladder cancer in the us every year with nonmuscleinvasive bladder cancer nmibc accounting for up to of all newly diagnosed cases
radical cystectomy the removal of the bladder and nearby structures and organs is currently recommended for nmibc patients who fail standardofcare bacillus calmetteguérin bcg immunotherapy however as nmibc usually affects older patients many may be unwilling or unfit to undergo this procedure
tar is an investigational targeted releasing system which enables the controlled release of the chemotherapy drug gemcitabine into the bladder this increases the amount of time the drug delivery system spends in the bladder and sustains local drug exposure according to jj
cohort two of the phase b sunrise trial has been evaluating tar as a monotherapy in patients with bcgunresponsive highrisk nmibc with carcinoma in situ who are ineligible for or decline radical cystectomy
results demonstrated a centrally confirmed complete response cr rate of with of crs achieved at the first disease assessment at week and four of five patients who have completed two years of treatment remaining in cr
the estimated oneyear duration of response rate is with median followup in responders of weeks additionally remained in cr at the data cutoff in january and none of the responders progressed to muscleinvasive bladder cancer or metastasis
“the high cr rate and durability of these responses observed in patients treated with tar underscores the potential of this treatment approach for patients with bcgunresponsive highrisk nmibc” said presenting author joseph jacob department of urology at upstate medical university
sunrise is also evaluating tar which has already been granted breakthrough therapy designation by the us food and drug administration in combination with the investigational antipd monoclonal antibody cetrelimab or cetrelimab alone in the same patient population
christopher cutie vice president disease area leader bladder cancer jj innovative medicine said “these results reinforce the potential of tar to transform the treatment landscape and our ongoing dedication to address unmet needs for patients facing this challenging disease”
article by emily kimber
th may
from research
johnson johnson nonmuscleinvasive bladder cancer oncology sunrise tar
subscribe to our email news alerts
latest jobs from pharmarole
account specialist respiratory kent medway account specialist respiratory kent medway
territory sales manager ostomy care wales south mids territory sales manager ostomy care wales south mids
key account manager urology east anglia beds bucks key account manager urology east anglia beds bucks
territory sales manager north london east anglia territory sales manager north london east anglia
integrated care specialist north west yorkshire integrated care specialist north west yorkshire
territory sales manager ostomy care wales south mids territory sales manager ostomy care wales south mids
latest content
novo nordisk’s semaglutide approved by mhra to prevent cardiovascular event risk
nhs figures reveal record number of people in england being diagnosed with dementia
merck’s investigational rsv monoclonal antibody clesrovimab shown to protect infants
gsk’s viiv shares positive headtohead results for twodrug hiv regimen dovato
researchers develop ai model to identify breast cancer stages and progression
latest intelligence
the omnichannel wonderland of opportunities
women in pharma
dementia – risk factors research and treatment
collaborating for change in rheumatology
pharma’s content conundrum
quick links
digital handbook
the gallery
healthcare glossary
how to advertise
orphan drugs and rare dis
pme supplements
social media hub
webinars
about us
privacy
terms and conditions
sitemap
pmgroup worldwide ltd
subscribeunsubscribe
about us
privacy
terms and conditions
sitemap
pmgroup worldwide ltd
subscribeunsubscribe
blob
to provide the best experiences we use technologies like cookies to store andor access device information consenting to these technologies will allow us to process data such as browsing behaviour or unique ids on this site not consenting or withdrawing consent may adversely affect certain features and functions privacy policy website terms and conditions
essentialessentialstatisticsstatisticsmarketingmarketing
accept cookiessave settings
x
cookie settings")
```
## Training Details
### Training Set Metrics
| Training set | Min | Median | Max |
|:-------------|:----|:--------|:-----|
| Word count | 275 | 1267.35 | 4278 |
| Label | Training Sample Count |
|:------|:----------------------|
| 0 | 10 |
| 1 | 10 |
### Training Hyperparameters
- batch_size: (16, 16)
- num_epochs: (2, 2)
- max_steps: -1
- sampling_strategy: oversampling
- num_iterations: 20
- body_learning_rate: (2e-05, 2e-05)
- head_learning_rate: 2e-05
- loss: CosineSimilarityLoss
- distance_metric: cosine_distance
- margin: 0.25
- end_to_end: False
- use_amp: False
- warmup_proportion: 0.1
- seed: 42
- eval_max_steps: -1
- load_best_model_at_end: False
### Training Results
| Epoch | Step | Training Loss | Validation Loss |
|:-----:|:----:|:-------------:|:---------------:|
| 0.02 | 1 | 0.2562 | - |
| 1.0 | 50 | 0.0028 | - |
| 2.0 | 100 | 0.0008 | - |
### Framework Versions
- Python: 3.11.0rc1
- SetFit: 1.0.3
- Sentence Transformers: 2.6.1
- Transformers: 4.39.2
- PyTorch: 2.2.2+cpu
- Datasets: 2.18.0
- Tokenizers: 0.15.0
## Citation
### BibTeX
```bibtex
@article{https://doi.org/10.48550/arxiv.2209.11055,
doi = {10.48550/ARXIV.2209.11055},
url = {https://arxiv.org/abs/2209.11055},
author = {Tunstall, Lewis and Reimers, Nils and Jo, Unso Eun Seo and Bates, Luke and Korat, Daniel and Wasserblat, Moshe and Pereg, Oren},
keywords = {Computation and Language (cs.CL), FOS: Computer and information sciences, FOS: Computer and information sciences},
title = {Efficient Few-Shot Learning Without Prompts},
publisher = {arXiv},
year = {2022},
copyright = {Creative Commons Attribution 4.0 International}
}
```